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Chronic respiratory disease (CRD), comprised mainly of asthma and chronic 
obstructive lung disease (COPD), is responsible for significant morbidity and 
mortality worldwide. Although asthma and COPD cannot be cured, they can be 
controlled using appropriate medications. Poorly controlled CRD is associated with 
significantly poorer quality of life and mortality for patients, an increased burden on 
the healthcare system, and a negative economic impact due to loss of productivity. 
CRD is underdiagnosed, undertreated and poorly controlled, especially in low- and 
middle-income countries. Improving control of CRD would result in improved quality 
of life for patients and a reduced burden on the healthcare system and economy. 
Despite the increase in burden of CRD globally, limited data are available on the 
burden of CRD in South Africa. Such data are essential if appropriate measures are to 
be put in place to address these needs. 
In this mini-dissertation, I aimed to describe the symptomatic burden of disease and 
levels of treatment in adults with CRD attending primary healthcare facilities in the 
Western Cape. Additionally, I aimed to identify predictors of both the quality of life 
and receipt of treatment in this population. 
This study was a secondary analysis of the baseline data collected during the Primary 
Care 101 (PC101) trial, a large pragmatic cluster randomised controlled trial 
conducted in 38 primary healthcare clinics in the Eden and Overberg districts of the 
Western Cape between 2011 and 2012. The study population for the current study 
was limited to the 1 157 participants enrolled in the CRD cohort of the PC101 trial. 
Part A of this mini-dissertation comprises the research protocol which was submitted 
to, and approved by, the University of Cape Town Faculty of Health Sciences Human 
Research Ethics Committee. 
Part B comprises the literature review, which outlines the prevalence and increasing 
burden of CRD both globally and in South Africa. As demonstrated in many studies 
from a wide variety of countries, the literature supports that CRD is underdiagnosed, 
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undertreated, and has a significant impact both on affected individuals as well as 
healthcare systems and economies. 
Part C includes the journal-ready manuscript. Findings confirm a high burden of 
symptoms and activity limitation, indicating a poor quality of life amongst this 
population. Findings also suggest undertreatment, with 40% of patients not receiving 
treatment for CRD despite being symptomatic. More respiratory symptoms were 
associated with male sex, a positive screen for depression, previous tuberculosis, 
previous smoking, more activity limitation and current receipt of treatment for CRD. 
Greater activity limitation was associated with unemployment, diabetes, a positive 
screen for depression, more respiratory symptoms, recent hospital admission and 
receiving treatment for CRD. Participants were more likely to be on treatment if they 
were older, more symptomatic or had greater activity limitation due to their 
respiratory condition. Treatment was less likely in participants who screened positive 
for depression, were current smokers, had increased recent clinic visits or a recent 
hospital admission. 
In summary, we found a high burden of symptoms and activity limitation, and of 
undertreatment, possibly contributed to by under-recognition of respiratory disease  
among patients attending primary care clinics in the Western Cape. Depression, a 
history of previous tuberculosis and unemployment are common features in such 
patients. Potential interventions are to introduce a systematic approach to CRD 
diagnosis in primary care clinics that includes screening for depression, improving 
availability of essential drugs for the management of CRD, and preventive strategies 
such as more effective tuberculosis control, and support and pharmacotherapy to 
assist smokers to quit. 
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A1. STUDY SYNOPSIS 
 
The World Health Organisation (WHO) defines chronic respiratory disease (CRD) as 
‘chronic diseases of the airways and other structures of the lung’, with the majority 
being asthma and chronic obstructive pulmonary disease (COPD).1 CRD is 
responsible for significant morbidity and mortality worldwide.2 In 2015, the estimated 
global prevalence of asthma was 358 million and 174 million for COPD.3 The burden 
of CRD is increasing globally, with COPD increasing by 17% between 2005 and 
2015, and asthma by 9.5%.3 
 
Although asthma and COPD cannot be cured, they can be controlled using 
appropriate medications. Poorly controlled CRD is associated with significantly 
poorer quality of life and mortality for patients, an increased burden on the healthcare 
system due to increased utilisation of resources, and a negative economic impact due 
to loss of productivity and premature retirement from the workforce.4,5 In general, and 
especially in low- and middle-income countries, CRD is underdiagnosed, undertreated 
and poorly controlled.2,6,7 Improving control of CRD would result in improved quality 
of life for patients and a reduced burden on the healthcare system and economy. 
 
Despite the increase in burden of CRD globally, there is a lack in data surrounding the 
burden of CRD in South Africa.2,7 The WHO has developed a strategy for the 
prevention and control of CRD, with one of the objectives being ‘better surveillance 
to map the magnitude of chronic respiratory diseases and analyse their determinants 
with particular reference to poor and disadvantaged populations, and to monitor future 
trends’.8 Limited data are available on the burden of CRD in South Africa, and 
particularly on the availability and efficacy of measures to control them at healthcare 
provider level. Such data are essential if appropriate measures are to be put in place to 
address these needs. 
 
The aim of this study is to describe the symptomatic burden of disease and levels of 
treatment in adults with CRD attending primary healthcare facilities in the Western 
Cape. The study also aims to identify predictors of both the quality of life and receipt 
of treatment in this population. 
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This will be a secondary analysis of data collected during the Primary Care 101 
(PC101) trial, a large pragmatic cluster randomised controlled trial conducted in 38 
primary healthcare clinics in the Eden and Overberg districts of the Western Cape 
between 2011 and 2012. The primary objective of the trial was to test the 
effectiveness of the PC101 programme in improving management of non-
communicable diseases at a primary healthcare level. The trial recruited four patient 
cohorts; comprising adult clinic attendees with hypertension, diabetes, CRD and/or a 
positive screen for depression. Some results of the study have been reported. The 
current analysis and report will be restricted to the CRD cohort. 
 
There are minimal risks associated with this study other than the risk of loss of 
confidentiality. To prevent this, the dataset will remain anonymous and all data will 
be stored in password-protected files. There will be no direct benefits for participants 
in this study. However, findings of this study may inform policy and improve the 
management of CRD in primary healthcare facilities in South Africa, and reduce the 
burden and severity of CRD in the community. 
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The World Health Organisation (WHO) defines chronic respiratory disease (CRD) as 
‘chronic diseases of the airways and other structures of the lung’, with the majority 
being asthma and chronic obstructive pulmonary disease (COPD).1 Identified risk 
factors for CRD include exposure to tobacco smoke, air pollution, occupational 
chemicals and dusts, frequent lower respiratory tract infections in childhood and 
previous pulmonary tuberculosis (TB).1 Although CRD is not curable, various 
treatments are effective in reducing symptoms, exacerbations and complications of 
disease, and in improving the quality of life and survival of people affected by these 
conditions.1 
 
Non-communicable diseases (NCDs) are the leading cause of death globally, 
responsible for 65% of all deaths, with the majority of these occurring in low and 
middle-income countries.4 CRD is now reaching epidemic proportions in many low-
income areas around the world and is responsible for a significant amount of 
morbidity and mortality worldwide.2 According to The Global Burden of Disease 
Study in 2015, the global prevalence of CRD is estimated to be 514 million, with the 
majority of these cases being due to asthma (358 million) and COPD (174 million).3 
The estimated number of years lived with disability (YLDs) globally in 2015 was 30 
million for CRD overall, 15 million for asthma and 12 million for COPD. This placed 
asthma as the eleventh leading cause of YLDs globally and ninth in South Africa, 
with COPD as the fourteenth leading cause globally.3 An estimated 3.8 million people 
died from CRD in 2015, with 3.2 million of these deaths due to COPD and almost 
400 000 due to asthma.9 COPD is currently the tenth leading cause of years of life lost 
(YLLs) globally, and fourth leading cause of YLLs amongst countries with a middle 
socio-demographic index.9  
 
The Burden of Obstructive Lung Disease (BOLD) Study, conducted in 12 
international sites, reported an estimated global prevalence of COPD Stage II and 
higher of 10.1% (11.8% for men and 8.5% for women).10 The WHO’s World Health 
Survey of 2002-2004 reported a global prevalence of doctor-diagnosed and/or receipt 
of treatment for asthma of 4.5% in 18-45 year olds.4 However, 8.6% of subjects 
surveyed reported symptoms of asthma in the preceding 12 months.  
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The burden of CRD in South Africa has not been well documented.2 The South Africa 
Demographic and Health Survey in 2003, based on self-reporting, reported an asthma 
prevalence of 3.1% in men and 4.4% in women over 15 years old.2 For 
emphysema/chronic bronchitis, the reported prevalence was 2.0% in men and 2.6% in 
women.2 However, in the BOLD study, the Cape Town site showed an overall COPD 
prevalence of 23.8% and a stage 2 or higher COPD prevalence of 19.1%, significantly 
higher than the study’s global estimate of 10.1%.11 The Cape Town study, performed 
in 2005, had the highest estimated prevalence rates of COPD amongst the 12 
international sites included in the study.11,12 The WHO’s World Health Survey of 
2002-2004 reported that amongst the 18-45 year olds surveyed in South Africa, 10-
15% reported symptoms of asthma in the preceding 12 months, compared to the 
global average of 8.6%.4 
 
The burden of CRD is increasing globally. Between 2005 and 2015, the prevalence of 
CRD increased by 12%, COPD by 17% and asthma by 9.5%.3 The past 20 years have 
shown an increase in NCDs in South Africa, likely due to an increase in risk factors as 
well as an aging population due to demographic change.2,7 This increase has been 
seen in both urban and rural populations, with an increased burden amongst poorer 
people living in urban areas.2,7 Due to the overwhelming prevalence of communicable 
diseases in South Africa such as TB and HIV, the prevention, diagnosis and 
management of NCDs including CRD has previously been marginalised.2 With 
antiretroviral therapy now widely available, mortality from HIV has declined and the 
burden of NCDs has increased and is expected to continue to do so.2 The increase in 
NCDs results in an increased demand for chronic disease care and places further 
pressure and burden on the healthcare system.2,7 Due to the burden and suffering 
associated with these conditions, the WHO has identified CRD, along with 
cardiovascular diseases, diabetes, and cancers, as a priority issue to be targeted by 
national governments.4,13  
 
CRD, especially in low- and middle-income countries, is underdiagnosed, 
undertreated and poorly controlled.2,6,7 Although effective medications for asthma 
have been available for many years, asthma remains poorly controlled with excessive 
hospital admissions and avoidable deaths still common.4  
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CRD has a significant impact on affected individuals as well as healthcare systems 
and economies. Acute exacerbations of COPD are associated with worsening of 
respiratory symptoms and functional limitation.5 People with frequent COPD 
exacerbations have significantly poorer quality of life compared to those with less 
frequent exacerbations, and a higher rate of lung function loss.5 Uncontrolled asthma 
reduces quality of life due to both the burden of symptoms and its effect on mental 
and social wellbeing. Asthma may affect a persons ability to work, resulting in 
increased emotional and financial stress.4 Uncontrolled CRD places an increased 
burden on the healthcare system due to increased utilisation of resources such as 
clinician and emergency visits, hospitalisations and medications.4 People with 
uncontrolled disease are less likely to be able to work, resulting in loss of productivity 
and an increased economic burden for a country.4  
 
Although asthma and COPD cannot be cured, they can be controlled using 
appropriate medications, with early diagnosis and initiation of treatment resulting in 
improved outcomes.4 The goal of treatment is to control symptoms and improve 
‘future risk’, that is, to prevent acute exacerbations, further worsening of health status 
and the development of comorbidities, and to minimise activity limitation arising 
from the condition.4 Appropriate treatment of COPD has been shown to reduce the 
frequency of acute exacerbations and to reduce the rate of deterioration in health 
status.5 Well controlled CRD results in a decrease in burden at both a personal level 
as well as on the healthcare system and economy.4  
 
In summary, CRD results in significant morbidity and mortality and can have a major 
impact at both an individual and a healthcare system level. CRD is underdiagnosed, 
inappropriately treated and poorly controlled. Controlling CRD would result in 
prevention of acute exacerbations, improved quality of life for patients and a reduced 
burden on the healthcare system. 
 
Despite the increase in burden, data surrounding prevalence, treatment and control of 
CRD in South Africa are lacking.2,7 The WHO has developed a strategy for the 
prevention and control of CRD, with one of the objectives being ‘better surveillance 
to map the magnitude of chronic respiratory diseases and analyse their determinants 
with particular reference to poor and disadvantaged populations, and to monitor future 
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trends’.8 More data is needed to establish the burden of CRD in South Africa so that 




A3. PURPOSE OF THE STUDY 
 
a) Aim of the study 
 
The aim of this study is to describe the symptomatic burden of disease and levels of 
treatment in adults with CRD in two districts of the Western Cape province. The 
study also aims to identify predictors of both disease-specific quality of life and 
receipt of treatment in clinic attendees with this diagnosis. 
 
b) Specific objectives 
 
1. To describe quality of life and levels of treatment in adults with CRD.  
 
2. To examine differences in patient, demographic and socioeconomic 
characteristics between those receiving treatment and those who are not. 
 
3. To identify patient characteristics associated with quality of life and receipt of 





a) Study design 
 
This will be a secondary analysis of data collected during the Primary Care 101 
(PC101) trial, a large pragmatic cluster randomised controlled trial conducted 
between 2011 and 2012 in primary healthcare facilities in the Eden and Overberg 
Districts of the Western Cape, South Africa. The main objective of the trial was to test 
the effectiveness of the PC101 programme in improving management of NCDs at a 
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primary healthcare level. The PC101 programme aims to improve the ability of 
clinicians (primarily nurses) to provide quality care to patients attending these 
facilities through use of a customised integrated patient management tool and training 
programme.6 In the PC101 trial, four adult patient cohorts were recruited and 
enrolled; attendees with hypertension, diabetes, CRD and/or a positive screen for 
depression. The current study will analyse the data from the CRD cohort only. 
 
b) Sample size  
 
As this was a secondary analysis, a sample size calculation was not performed. In the 
PC101 trial, a separate sample size was calculated for each of the four cohorts, with 
treatment intensification being used as the primary endpoint for the hypertension, 
diabetes and CRD cohorts. Sample size calculations were for two-sided tests and were 
powered at 85%, with calculations being increased by 20% to allow for loss to follow-
up during the trial. It was also taken into account that a large amount of co-morbidity 
was anticipated and participants with more than one condition were eligible for more 
than one cohort. The calculated required cluster size for the CRD cohort was 27 
participants per clinic, resulting in a total required sample size of 1 026 participants. 
This target was met and, following recruitment, the total number of participants in the 
cohort was 1 157. The full respiratory cohort will be used for this analysis. 
 
c) Study setting 
 
The PC101 trial was conducted in public sector primary healthcare clinics in the Eden 
and Overberg Districts of the Western Cape, South Africa. Together, these districts 
have a population of approximately 800 000 people. For clinics to be included in the 
study, they needed to provide services for NCDs at least 5 days a week and report 
more than 10 000 clinic visits per year. Of the clinics in the Eden district, 33 met 
these criteria. To achieve the required sample sizes, this number was supplemented 
with an additional 5 clinics from the adjacent Overberg district to reach a total of 38 
clinics. These clinics were mainly in medium-sized towns and rural areas, and were 
predominantly nurse-led with doctor support ranging from daily to sessional. 
Respiratory services offered included diagnosis and basic treatment of common 
respiratory conditions, with most clinics having access to peak flow meters and X-
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rays, but not to spirometry. The populations served by these clinics are generally of 
poor socioeconomic status with high levels of unemployment. Clinics were 
randomised to receive both implementation and training in the use of the PC101 
patient management tool (the intervention) or to continue with routine care (the 
control). 
 
d) Study population 
 
The study population of the PC101 trial consisted of adults with hypertension, 
diabetes, CRD and/or a positive screen for depression, accessing healthcare at primary 
care level facilities in the Eden or Overberg Districts of the Western Cape. 
 
To be included in the CRD cohort, participants needed to have one of the following: 
- Self-reported asthma, chronic bronchitis or emphysema on treatment, or 
- Cough or difficulty breathing for more than 2 weeks and not on treatment for 
TB in the past 3 months 
 
They also needed to be at least 18 years of age, able to actively participate in an 
interviewer-administered questionnaire, likely to stay in the same area for the duration 
of the trial and provide written consent to participate in the study. Patients were 
excluded if they did not meet the eligibility criteria or were judged unable to provide 
informed consent. 
 
For the purposes of this study, no further inclusion or exclusion criteria will be 
applied. 
 
e) Recruitment and enrollment 
 
Recruitment for the PC101 trial was done by trained fieldworkers from local 
communities. Fieldworkers approached patients in clinic waiting areas and invited 
them to participate in the trial. Patients were screened in a private area in the clinic 
and, if they fulfilled the eligibility criteria and signed the consent form, were enrolled 
into the trial. 
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For the purposes of this study, the participants recruited into the CRD cohort of the 
trial will be used as the study sample and no additional recruitment or enrollment will 
occur. 
 
f) Research procedures and data collection methods 
 
In the PC101 trial, a trained fieldworker conducted a baseline interview with each 
participant immediately after enrollment. To allow for privacy, this interview was 
done in a separate room in the clinic with only the fieldworker and participant present. 
A standardised structured questionnaire was administered by the fieldworker and 
conducted in the participant’s language of choice (English, Afrikaans or isiXhosa). 
The questionnaire included questions related to basic demographics, socioeconomic 
status, medical history, smoking history, current state of health, severity of symptoms 
and levels of healthcare utilisation. To assess quality of life in the CRD cohort, the St 
George’s Respiratory Questionnaire (SGRQ) was used and scores were calculated for 
both the symptoms and activity domains. As there is no tested translated isiXhosa 
version of the SGRQ, participants completing the interview in isiXhosa were 
excluded from this section of the questionnaire. Baseline anthropometric 
measurements were taken from each participant, including blood pressure, weight, 
height and waist circumference. All questionnaire responses and measurements were 
entered by the fieldworker into an electronic hand-held device (netbook) at the time of 
the interview. Fieldworkers then collected all prescription data by photocopying 
prescription charts for the year preceding the baseline interview. This data was 
reviewed by the medically qualified trial manager who was responsible for identifying 
medications used to treat hypertension, diabetes, CRD and depression at the time of 
the interview.  
 
Participants were re-interviewed 14 months after their baseline interview. Participants 
were reminded of their interviews with letters and text messages. Those who missed 
their interviews were traced by either a phone call or home visit. Similar questions 
were asked and the measurements repeated. The SGRQ symptoms and activity 
domain questions were repeated for participants in the CRD cohort, again excluding 
those who chose to complete the questionnaire in isiXhosa. Responses were again 
entered by the fieldworker into an electronic hand-held device. Prescription charts for 
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the previous 14 months were collected by the fieldworkers and were again analysed 
by the trial manager. 
 
Fieldworkers were supervised to ensure quality control of the data. If unusual values 
were entered into the electronic device, alert messages were sent to the fieldworker to 
check and correct these if necessary. Data was monitored by the research team to 
identify unusual values or trends, and all prescription data was double entered. 
 
For this study, a secondary data analysis will be performed using the data collected 
from the CRD cohort in the PC101 trial. No further primary data collection will take 
place. 
 
g) Data management 
 
An anonymous dataset will be obtained from the PC101 trial manager and used for 
secondary data analysis. For the purposes of this study, no knowledge of participant 
identity will be required. The data will be stored in a Microsoft Excel password-
protected file and will not be shared with anyone not directly involved in this study. 
 
h) Data analysis 
 
Exploratory data analysis will look at the distribution and summary statistics of each 
individual variable. Categorical variables will be assessed using frequency tables. 
Continuous variables will be assessed using histograms as well as means and standard 
deviations for normally distributed data, and medians and interquartile ranges for data 
not normally distributed.  
 
Simple associations between each of the outcome variables and the covariates will be 
assessed. Scatterplots and correlation analyses will be used for continuous variables, 
contingency tables for categorical variables, and box plots for one continuous and one 
categorical variable. 
 
Baseline characteristics will be shown for the full CRD cohort, as well as by treatment 
status at baseline. Differences in characteristics between participants receiving and 
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not receiving treatment will be tested using univariate logistic regression models. 
Each model will include only the participant characteristic as the explanatory 
variable, with the outcome being treatment status, and will be adjusted for an effect 
due to the cluster sampling technique used. 
Multiple linear regression models will be used to identify predictors of quality of life, 
with quality of life measured using the SGRQ symptoms and activity domain scores. 
Models will initially be built using a backward selection approach, with all covariates 
initially being included in the model. Covariates with a p-value of ≥ 0.2 will be 
removed in a step-wise approach and the model repeatedly re-fitted until a final model 
is identified including only statistically significant covariates. Using a forward 
selection approach, each of the dropped covariates will then be added back into the 
final model one at a time to ensure no significant predictors have been omitted. 
Multiple logistic regression models will be used to identify predictors of treatment, 
built using the same approach outlined above. All models will account for the cluster 
sampling method used. 
 
Stata 13.0 (Stata Corporation, College Station, Texas) will be used as the statistical 
software package for all analyses. A level of significance of 0.05 will be used for all 
statistical tests.  
 
 
A5. ETHICAL CONSIDERATIONS 
 
The PC101 trial received ethics approval from the University of Cape Town (UCT) 
Faculty of Health Sciences Human Research Ethics Committee (HREC REF 
119/2010). This approval has been renewed annually and is currently valid until 30 
July 2017. Permission for recruitment and research to occur in provincial primary 
healthcare facilities was granted by the Western Cape Provincial Department of 
Health (Reference 18/19/RP152/2010).  
 
Permission to use the trial data for this secondary analysis has been granted by a 
principal investigator of the trial. This study protocol will be submitted to both the 
School of Public Health Departmental Research Committee and the UCT Faculty of 
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Health Sciences Human Research Ethics Committee for approval of secondary data 
analysis as described in this protocol. 
 
a) Risks and benefits 
 
As this is a secondary data analysis, there are minimal risks associated with this study 
other than the risk of loss of confidentiality. To prevent this, only an anonymous 
dataset will be obtained from the trial manager. All data will be stored in password-
protected files and will not be shared with anyone not directly involved in the study.  
 
There will be no direct benefits for participants in this study. However, findings of 
this study may highlight the burden of CRD and identify factors associated with 
treatment and quality of life amongst adults with CRD. Identifying these associations 
may inform policy change with improved management of CRD, and a reduction in the 
burden and severity of CRD in the community. 
 
b) Informed consent process 
 
In the PC101 trial, all patients approached by fieldworkers in the clinic waiting areas 
were given a patient leaflet to read. These were available in English, Afrikaans and 
isiXhosa and a copy was given in the language chosen by the patient. Patients who 
were interested in participating in the trial were then screened by a fieldworker in a 
private area of the clinic, in the language of their choice (English, Afrikaans or 
isiXhosa). 
 
A detailed patient information sheet was provided for patients found to be eligible for 
the study. The information sheet described the purpose of the study, possible risks and 
benefits of participation, an overview of the study procedure and confidentiality. 
 
Patients that were eligible for the trial were informed of what the trial would require, 
including a structured questionnaire and basic anthropometric measurements done at 
both baseline and repeated after 14 months. Consent was requested to review hospital 
records in the case of admission, and for identity numbers to track vital status if 
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necessary. Only participants that agreed and signed the consent form were included in 
the trial. 
 
As this is a secondary data analysis of an anonymous dataset, no individual consent 
will be obtained for this study. All participants included in this study have already 
provided informed signed consent to participate in the PC101 trial. 
 
c) Privacy and confidentiality 
 
To ensure privacy in the trial, participants were screened and interviewed in a private 
area of the clinic with only the participant and the fieldworker present. To ensure 
confidentiality, a unique patient identification number was assigned to each 
participant in the trial and this number was used on all datasets. All netbooks were 
locked in the clinic when not in use and all fieldworkers and members of the research 
team signed a confidentiality agreement.  
 
For this study, an anonymous dataset will be obtained from the trial manager and no 
knowledge of participant identity will be required. Patient consent forms will not be 
reviewed for this study. The data will be stored in a Microsoft Excel password-
protected file and will not be shared with anyone not directly involved in the study. 
 
 
A6. REIMBURSEMENT FOR PARTICIPATION 
 
The PC101 trial provided all participants returning for the follow-up interview with a 
cash voucher for a local grocery store to the value of ZAR100. This amount 
compensated for costs incurred to attend the follow-up interview. As this study will 
include secondary data analysis only, there will be no further compensation or 
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A7. USE OF INFORMATION & PUBLICATION 
 
The study findings will be collated in a journal-ready manuscript and submitted as the 
mini-dissertation component of the author’s Masters in Public Health degree. The 
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This study will include only secondary data analysis which will be done by the author 
as the mini-dissertation component of the Masters in Public Health degree. Data 
analysis will be conducted in the author’s own time and no funding will be required. 
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Chronic respiratory disease (CRD) is responsible for significant morbidity and 
mortality worldwide, with the burden increasing globally. Although CRD cannot be 
cured, it can be controlled using appropriate medications. Poorly controlled CRD is 
associated with a poorer quality of life for patients as well as an increased burden on 
the healthcare system and a negative economic impact. In general, and especially in 
low- and middle-income countries, CRD is underdiagnosed, undertreated and poorly 
controlled. Improving control of CRD would result in improved quality of life for 
patients and a reduced burden on the healthcare system and economy. 
 
The aim of this literature review is to describe the prevalence and burden of CRD 
both globally and in South Africa, as well as to describe the underdiagnosis and 




B2: LITERATURE SEARCH STRATEGY 
 
The Pubmed and Google Scholar online databases were used to search for relevant 
literature. Multiple searches were conducted using the terms ‘chronic respiratory 
disease’ or ‘asthma’ or ‘COPD’ with various combinations including ‘prevalence’, 
‘underdiagnosis’, ‘undertreatment’, ‘quality of life’, ‘control’, ‘consequences’, 
‘impact’, ‘productivity’, and ‘economic’. The search was restricted to English 
language publications, with no restrictions being placed on study design or year of 
publication. Titles of articles were scanned by the author, and abstracts of relevant 
articles reviewed. Full text of the studies relevant to the aim and objectives of the 
literature review were retrieved and reviewed. Any further relevant studies cited in 
these publications that were not retrieved in the database search were also reviewed. 
Further to the online database searches, reports by both national and international 
bodies were reviewed. These included the latest World Health Organisation (WHO) 
and South African Department of Health reports pertaining to CRD and non-
communicable diseases. A small number of other documents were reviewed as 
recommended by supervisors, such as unpublished theses. 
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B3: SUMMARY OF LITERATURE 
 
Definition of chronic respiratory disease 
 
The WHO defines CRD as ‘chronic diseases of the airways and other structures of the 
lung’, with the majority being asthma and chronic obstructive pulmonary disease 
(COPD).1 Identified risk factors for CRD include exposure to tobacco smoke, air 
pollution, occupational chemicals and dusts, frequent lower respiratory tract 
infections in childhood and previous pulmonary tuberculosis (TB).1 Although CRD is 
not curable, various treatments are effective in reducing symptoms, exacerbations and 
complications of disease, and in improving the quality of life and survival of people 
affected by these conditions.1 
 
The global prevalence of chronic respiratory disease 
 
Non-communicable diseases (NCDs) are currently the leading cause of death 
globally.2,3 In 2008, 36 of the 57 million deaths globally (63%) were due to NCDs 
with the leading causes being cardiovascular diseases (17 million), cancers (7.6 
million), chronic respiratory disease (4.2 million) and diabetes (1.3 million).3 Most of 
this burden is carried by low- and middle-income countries, with 80% of NCD deaths 
occurring in these areas.3 
 
CRD is now reaching epidemic proportions in many low-income areas around the 
world and are responsible for a significant amount of morbidity and mortality 
worldwide.4 According to The Global Burden of Disease Study in 2015, there are an 
estimated 514 million cases of CRD globally, with the majority of these being asthma 
(358 million) and COPD (174 million).5 The estimated number of years lived with 
disability (YLDs) globally in 2015 was 30 million for CRD overall, 15 million for 
asthma and 12 million for COPD. This placed asthma as the 11th leading cause of 
YLDs globally and 9th in South Africa, with COPD as the 14th leading cause 
globally.5 An estimated 3.8 million people died from CRD in 2015, with 3.2 million 
of these deaths due to COPD and almost 400 000 due to asthma.6 COPD is currently 
the 10th leading cause of years of life lost (YLLs) globally, and 4th leading cause of 
YLLs amongst countries with a middle socio-demographic index.6 CRD accounted 
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for 97 million disability adjusted life years (DALYs) in 2015, with COPD being the 
12th leading cause of global DALYs and 3rd leading cause amongst those aged 65-79 
years. Asthma was the 25th leading cause of global DALYs.7 
 
The Burden of Obstructive Lung Disease (BOLD) Study, published in 2007, assessed 
the burden of COPD in high- and low-income countries. Conducted in 12 
international sites and including 8 775 participants, the study reported an estimated 
global prevalence of COPD Stage II and higher of 10.1% (11.8% for men and 8.5% 
for women).8 
 
Between 2002 and 2004, the WHO’s World Health Survey measured the prevalence 
of asthma amongst 177 496 individuals between age 18 and 45 years living in 70 
countries. They reported a global prevalence of doctor-diagnosed and/or receipt of 
treatment for asthma of 4.5%, however, 8.6% of subjects surveyed reported symptoms 
of asthma in the preceding 12 months.2 The prevalence of asthma varied widely, with 
the highest figures seen in Australia, Northern and Western Europe and Brazil. There 
is little known about the prevalence amongst the middle-aged and elderly, due to both 
a lack in data as well as the difficulty in distinguishing asthma from COPD in older 
patients.2 
 
The prevalence of chronic respiratory disease in South Africa 
 
The burden of CRD in South Africa has not been well documented.4 The South 
African Demographic and Health Survey in 2003, based on self-reporting, reported an 
asthma prevalence of 3.1% in men and 4.4% in women over 15 years old.4 For 
emphysema/chronic bronchitis, the reported prevalence was 2.0% in men and 2.6% in 
women.4 However, in the BOLD study, the Cape Town site showed an overall COPD 
prevalence of 23.8% and a stage II or higher COPD prevalence of 19.1%, 
significantly higher than the study’s global estimate of 10.1%.9 The Cape Town study, 
performed in 2005, had the highest estimated prevalence rates of COPD amongst the 
12 international sites included in the study.9,10 The WHO’s World Health Survey of 
2002-2004 reported that amongst the 18-45 year olds surveyed in South Africa, 10-
15% reported symptoms of asthma in the preceding 12 months, compared to the 
global average of 8.6%.2 Comparison of national age-standardized mortality rates for 
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asthma between 2001 and 2010 show much variation, with South Africa reporting the 
highest mortality rate of 280 per million population.2 The second South African 
National Burden of Disease Study assessed mortality trends in the country from 1997 
to 2012 and reported that, in 2012, COPD was the 3rd leading cause of death amongst 
Caucasians, 4th amongst Coloureds and 9th amongst Indians/Asians.11 COPD also 
ranked as the 8th top cause of YLLs in both the Western and Northern Cape provinces, 
with 3.5% of years of life lost due to COPD in the Western Cape and 2.7% in the 
Northern Cape. 
 
The increasing burden of chronic respiratory disease 
 
The burden of CRD is increasing globally. Between 2005 and 2015, the prevalence of 
CRD increased by 12%, with COPD by 17% and asthma by 9.5%.5 The past 20 years 
have shown a substantial increase in the burden of NCDs in South Africa, particularly 
due to cardiovascular diseases, diabetes, COPD and cancers.4,11,12 This is likely to be 
due to an increase in risk factors for these conditions as well as a growing and aging 
population.4,11,12 This increase has been seen in both urban and rural populations, with 
a larger burden amongst poorer people living in urban areas.4,11,12 Due to the 
overwhelming prevalence of communicable diseases in South Africa such as TB and 
HIV, the prevention, diagnosis and management of NCDs including CRD has 
previously been marginalised.4 With antiretroviral therapy now widely available, 
mortality from HIV has declined and the burden of NCDs has increased and is 
expected to continue to do so.4 The increase in NCDs results in an increased demand 
for chronic disease care and places further pressure and burden on the healthcare 
system.4,12 This increase in burden led to the development of the South African 
Strategic Plan for the Prevention and Control of Non-Communicable Diseases 2013-
2017, which focuses on both primary prevention as well as and management of the 
high burden of NCDs and their risk factors.13 Due to the burden and suffering 
associated with these conditions, the WHO has also identified CRD, along with 
cardiovascular diseases, diabetes, and cancers, as a priority issue to be targeted by 




The Burden of Chronic Respiratory Disease in the Western Cape 
Part B: Literature review 
6 
The underdiagnosis and undertreatment of chronic respiratory disease 
 
Chronic respiratory disease, especially in low- and middle-income countries, is under-
diagnosed, under-treated and poorly controlled.4,12,15,16 Although effective 
medications for asthma have been available for many years, asthma remains poorly 
controlled with excessive hospital admissions and avoidable deaths still common.2  
 
Underdiagnosis has been demonstrated in many studies from a wide variety of 
countries. The PREPOCOL Study, a cross-sectional, population-based study 
conducted between 2003 and 2004 and including 5 539 participants over the age of 40 
years, assessed the prevalence of COPD in five Colombian cities. Of those meeting 
the diagnostic criteria for COPD, 87.4% were undiagnosed.17 Following the 
PREPOCOL Study, Gonzalez-Garcia et al assessed the prevalence and diagnosis of 
asthma amongst the same population. They reported that 69.9% of asthma cases were 
undiagnosed, with this figure increasing to 79.0% in participants aged 64 years or 
older.18 Following the PLATINO Study, a population-based epidemiological study 
assessing COPD prevalence in 5 Latin American cities in 2002, a 9-year follow-up 
study was conducted in the study site of Sao Paulo, Brazil. In the original study, 
prevalence of spirometry-confirmed COPD in Sao Paulo was reported as 15.8%, with 
87.5% of these cases being undiagnosed.19 Of those with a previous diagnosis, only 
16.7% reported receiving treatment. Participants in Sao Paulo were followed up over 
9 years and, of those who developed COPD during this period, 70.0% were 
undiagnosed.19 Lamprecht et al analysed data from 4 large epidemiologic surveys 
assessing the prevalence of COPD, including the PREPOCOL and PLATINO studies, 
as well as the BOLD and EPI-SCAN studies. Underdiagnosis rates amongst those 
with spirometry-confirmed COPD ranged from 50.0% in Lexington, United States, to 
98.3% in Ile-Ife, Nigeria, with an overall underdiagnosis rate of 81.4%.20  
 
The PUMA study, a multicenter, multinational, cross-sectional study, recruited 
participants over the age of 40 years with risk factors for COPD attending primary 
healthcare facilities in Argentina, Colombia, Venezuela and Uruguay. As part of this 
study, Casas Herrera et al assessed the underdiagnosis of COPD in primary care and 
found that, of the 1 540 participants who completed spirometry, 20.1% met the 
diagnostic criteria for COPD with 77% of these cases being undiagnosed.21 Martinez 
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et al conducted a cross-sectional analysis of American adults using 2 National Health 
and Nutritional Examination Surveys, run between 1988-1994 and 2007-2012. 
Amongst participants with spirometry-confirmed obstructive lung disease, 71.2% of 
participants in the earlier survey were undiagnosed and this figure was essentially 
unchanged at 72.0% in the following survey.22  
 
A population-based, epidemiological study by Llordes et al aimed to determine the 
prevalence of COPD amongst an adult Spanish population with a history of smoking 
and to assess the accuracy of diagnosis of COPD in primary care. A total of 1 738 
participants were included and findings reported that 56.7% of those with spirometry-
confirmed COPD were undiagnosed.23 Between 2003 and 2013, Colak et al 
conducted a prospective cohort study amongst the general population in Denmark to 
assess the prognosis of undiagnosed COPD. There was 95 288 individuals included in 
the study and, of those who met the criteria for COPD, 78% were undiagnosed.24  
 
Hill et al assessed the prevalence, accuracy of prior diagnosis and the nondiagnosis of 
COPD amongst an at-risk population attending primary healthcare services in 
Ontario, Canada between 2006 and 2007. Amongst the 1 003 participants who 
completed spirometry, the prevalence of COPD was 20.7% with 67.3% of these cases 
being previously undiagnosed.25 Using data from 8 215 adults who participated in the 
2001 annual Health Survey for England, Shahab et al described the prevalence and 
extent of underdiagnosis of COPD in England. The 2011 survey specifically focused 
on respiratory conditions and included assessment of lung function by spirometry. 
Findings showed a COPD prevalence of 13.3%, with 80% of these cases being 
undiagnosed.26 Even amongst those with severe or very severe COPD, levels of 
diagnosis were poor with 53.2% being undiagnosed. Jones et al conducted a 
retrospective cohort study using data collected from a UK general practice database 
between 1990 and 2009. By assessing patterns of health-care use amongst patients 
with confirmed COPD, they suggest that in the 5 years preceding the diagnosis of 
COPD, opportunities for diagnosis were missed in 85% of patients.27 
 
As well as being underdiagnosed, many studies have shown CRD to be undertreated. 
Using data from the PUMA Study, Jardim et al assessed treatment of COPD in 
patients utilising primary health care facilities in 4 Latin American countries. 
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Amongst those with spirometry-confirmed COPD, including those both diagnosed 
and undiagnosed, only 36.6% were receiving any medication.28 Amongst those with a 
previous diagnosis of COPD, this figure was 79.4%. Increased prescription of 
medication was associated with increased cough and dyspnoea, more severe disease, 
an acute exacerbation within the past year and less education. Ingebrigtsen et al 
assessed treatment amongst 5 812 patients with COPD participating in the 
Copenhagen General Population Study. Of those with FEV1 < 60%, only 30% of 
patients were prescribed treatment in the previous 12 months.29 Treatment was more 
likely with increased previous respiratory tract infections, increased dyspnea, more 
severe disease, previous COPD-related hospital admissions and previous smoking. 
Patients with comorbidity were less likely to receive treatment. Make et al conducted 
a retrospective analysis of United States (US) managed care and Medicare patients 
with COPD to assess patterns of medication use. Eligible patients had at least one 
admission or two outpatient visits for COPD, with a total of 51 000 participants 
included. Results showed significant undertreatment, with 59.1% of those with 
commercial insurance and 66.0% of those with Medicare not being prescribed any 
medication.30 In 2010, Sastre et al examined the use of medications amongst adult and 
adolescent patients with asthma in Europe and Canada. Although features of 
uncontrolled asthma such as frequent or severe symptoms, hospital admissions, 
emergency visits or unscheduled physician visits were commonly reported, most 
participants felt that their asthma was well controlled and undertreatment was high, 
with only 52% reporting daily use of a controller medication.31 Enright et al assessed 
the diagnosis and treatment of asthma amongst a population aged 65 years and older 
in the US. Apart from the underdiagnosis and asthma-related morbidity reported in 
this population, undertreatment was common with only 40% of patients receiving a 
bronchodilator, 30% receiving an inhaled corticosteroid, and 39% receiving no 
medication at all.32 These studies highlight the poor levels of treatment associated 
with CRD globally and suggest a need for improved treatment in order to achieve 
control of these conditions. 
 
The effect of poorly controlled chronic respiratory disease 
 
Chronic respiratory disease has a significant impact both on affected individuals as 
well as healthcare systems and economies. Acute exacerbations and uncontrolled 
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disease are associated with worsening health-related quality of life for patients, 
measured by assessing respiratory symptoms and functional limitation.33–36 
Miravitlles et al followed 336 Spanish patients with COPD over a 2-year period to 
evaluate the impact of acute exacerbations on their health-related quality of life. 
Findings suggested that frequent exacerbations were associated with significantly 
poorer quality of life amongst those with moderate COPD.34 A cross-sectional survey 
by Jones et al explored the health-related quality of life in 1 817 patients with COPD 
accessing primary healthcare facilities in 7 European countries. They found that 
patients experiencing an acute exacerbation had significantly worse quality of life 
scores compared to those with controlled disease.35 Nishimura et al examined the 
effect of exacerbations on the health status and pulmonary function of patients in 
Japan with COPD over a 6-month period. Although they did not show a significant 
effect on pulmonary function, those who experienced an exacerbation during the 
study period showed both a statistically and clinically significant decline in health 
status, with more frequent exacerbations causing more decline than less frequent 
exacerbations.33 Zamzam et al assessed the quality of life and its relationship with 
severity of disease amongst COPD patients in Egypt in 2011, with results showing 
increased severity of disease to be associated with poorer health-related quality of 
life.36 These studies demonstrate the importance in prevention of exacerbations to 
reduce deterioration in patient health status and quality of life. Treatment costs 
associated with CRD can be significant for patients, and the need to pay for medical 
consultations and treatment may result in patients not being able to afford other basic 
needs such as food, accommodation and education. The WHO estimates that by 
having to pay for health services, 100 million people are pushed into poverty every 
year.3 
 
In many low- and middle-income countries, CRD is often managed at secondary or 
tertiary care level with patients presenting to these facilities with more severe or 
complicated disease, resulting in an increased financial burden to the healthcare 
system.3 Poor control of CRD also places an increased burden on the healthcare 
system due to increased utilisation of resources such as clinician and emergency 
visits, hospitalisations and medications.2  
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People with uncontrolled disease are less likely to be able to work, resulting in loss of 
productivity, increased emotional and financial stress and an increased economic 
burden for a country.2 Taponen et al conducted a cross-sectional survey in Finland to 
assess factors associated with employment amongst 2 613 adults with asthma, and 
found that more frequent asthma symptoms were associated with higher levels of 
unemployment and work disability.37 In a national register-based study, Lokke et al 
assessed the economic consequences of COPD in Denmark between 1998 and 2010. 
They compared healthcare utilisation, procedures, medication, unemployment 
benefits and social transfer payments between 131 811 patients with COPD, and the 
same number of matched controls. Findings showed that patients with COPD had 
significantly higher rates of healthcare utilisation, medication use and higher 
socioeconomic costs.38 COPD was also associated with significantly lower 
employment rates, and lower income rates amongst those employed compared with 
those without COPD. These associations became stronger with more advanced 
disease. A systematic review by Chaker et al assessed the global impact of NCDs on 
macro-economic productivity, measured in DALYs, productivity costs and labour 
market participation.39 They suggest productivity losses due to COPD of 88 million 
USD per year in the US and 1.47 billion USD in Japan. Patients with COPD were at 
higher risk of reduced labor market participation, with almost 500 000 working days 
lost per year in the US due to their disease. They were more likely to work less hours 
and had a higher chance of unemployment, absenteeism and presenteeism (poorer 
work performance).39 
 
The benefit of control of chronic respiratory disease 
 
Although asthma and COPD cannot be cured, they can be controlled using 
appropriate medications, with early diagnosis and initiation of treatment resulting in 
improved outcomes.2 The goal of treatment is to control symptoms, to prevent acute 
exacerbations, further worsening of health status and the development of 
comorbidities, and to minimise activity limitation arising from the condition.2 
Appropriate treatment of COPD has been shown to reduce the frequency of acute 
exacerbations and to reduce the rate of deterioration in health status.33 Well controlled 
CRD results in a decrease in burden at both a personal level as well as on the 
healthcare system and economy.2  
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Despite the increase in burden, data surrounding prevalence, treatment and control of 
CRD in South Africa are lacking.4,12 The WHO has developed a strategy for the 
prevention and control of CRD, with one of the objectives being ‘better surveillance 
to map the magnitude of chronic respiratory diseases and analyse their determinants 
with particular reference to poor and disadvantaged populations, and to monitor future 
trends’.40 Further research is needed to more accurately establish the prevalence of 
CRD in South Africa and to assess the burden and severity of these conditions locally. 
More data is required to assess if CRD is being underdiagnosed and undertreated, as 
this would have a significant impact on both the burden of disease as well as disease 
severity. As primary healthcare facilities are the entry point for patients into our 
health system and are therefore responsible for diagnosing and treating the majority of 
patients with CRD in South Africa, it is important that research is conducted in 
primary healthcare settings. Obtaining this data would assist in establishing the 
burden of CRD in South Africa so that appropriate measures can be implemented to 




The Burden of Chronic Respiratory Disease in the Western Cape 




1.  World Health Organisation. Chronic respiratory diseases [Internet]. 2017. 
http://www.who.int/respiratory/en/ (accessed 29 May 2017). 
2.  Global Asthma Network. The Global Asthma Report 2014. Auckland, 2014. 
http://www.globalasthmareport.org/ (accessed 28 May 2017). 
3.  World Health Organisation. Global status report on noncommunicable diseases 
Geneva: WHO, 2010. http://www.who.int/nmh/publications/ncd-status-report-
2014/en/ (accessed 17 September 2017). 
4.  Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D, et al. 
The burden of non-communicable diseases in South Africa. Lancet. 
2009;374(9693):934–47. http://dx.doi.org/10.1016/S0140-6736(09)61087-4 
5.  GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, 
regional, and national incidence, prevalence, and years lived with disability for 
310 diseases and injuries, 1990 – 2015: a systematic analysis for the Global 
Burden of Disease Study 2015. Lancet. 2016;388:1545–602.  
6.  GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and 
national life expectancy, all-cause mortality, and cause-specific mortality for 
249 causes of death, 1980 – 2015: a systematic analysis for the Global Burden 
of Disease Study 2015. Lancet. 2016;388:1459–544.  
7.  GBD 2015 DALYs and HALE Collaborators. Global, regional, and national 
disability-adjusted life-years (DALYs) for 315 diseases and injuries and 
healthy life expectancy (HALE), 1990 – 2015: a systematic analysis for the 
Global Burden of Disease Study 2015. Lancet. 2016;388:1603–58.  
8.  Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- 
and low-income countries. Part I. The Burden of Obstructive Lung Disease 
(BOLD) Initiative. Int J Tuberc Lung Dis. 2008;12(7):703–8.  
9.  Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, 
et al. International variation in the prevalence of COPD (The BOLD Study): a 
population-based prevalence study. Lancet. 2007;370(9589):741–50. 
http://dx.doi.org/10.1016/S0140-6736(07)61377-4 
10.  Jithoo A. Respiratory symptoms and chronic obstructive pulmonary disease: 
Prevalence and risk factors in a predominantly low-income urban area of Cape 
Town, South Africa. University of Cape Town; 2006. 
	
The Burden of Chronic Respiratory Disease in the Western Cape 
Part B: Literature review 
13 
https://open.uct.ac.za/handle/11427/8913 
11.  Pillay-van Wyk V, Msemburi W, Laubscher R, Dorrington RE, Groenewald P, 
Glass T, et al. Mortality trends and differentials in South Africa from 1997 to 
2012: second National Burden of Disease Study. Lancet Glob Heal. 
2016;4:e642-53. http://dx.doi.org/10.1016/S2214-109X(16)30113-9 
12.  Folb N, Timmerman V, Levitt NS, Steyn K, Bachmann MO, Lund C, et al. 
Multimorbidity, control and treatment of non-communicable diseases among 
primary healthcare attenders in the Western Cape, South Africa. South African 
Med J. 2015;105(8):642–7. https://doi.org/10.7196/samjnew.8794 
13.  National Department of Health. Strategic Plan for the Prevention and Control 
of Non-Communicable Diseases 2013-17. South Africa. 2013. 
http://www.health.gov.za/index.php/2014-03-17-09-09-38/strategic-
documents/category/229-2015str?download=1057:strategic-plan-2015 
(accessed 17 September 2017). 
14.  World Health Organisation. Health in 2015: from MDGs, Millennium 
Development Goals to SDGs, Sustainable Development Goals. Geneva: WHO, 
2015. 
http://apps.who.int/iris/bitstream/10665/200009/1/9789241565110_eng.pdf?ua
=1 (accessed 7 June 2017). 
15.  Fairall LR, Folb N, Timmerman V, Lombard C, Steyn K, Bachmann MO, et al. 
Educational Outreach with an Integrated Clinical Tool for Nurse-Led Non- 
communicable Chronic Disease Management in Primary Care in South Africa : 
A Pragmatic Cluster Randomised Controlled Trial. PLoS Med. 
2016;13(11):e1002178. https://doi.org/10.1371/journal.pmed.1002178 
16.  Almagro P, Soriano JB. Underdiagnosis in COPD: a battle worth fighting. 
Lancet Respir. 2017;5:367–8. http://dx.doi.org/10.1016/S2213-2600(17)30133-
9 
17.  Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, 
et al. Prevalence of COPD in Five Colombian Cities Situated at Low, Medium, 
and High Altitude (PREPOCOL Study). Chest. 2008;133:343–9. 
https://doi.org/10.1378/chest.07-1361 
18.  Gonzalez-Garcia M, Caballero A, Jaramillo C, Maldonado D, Torres-Duque 
CA. Prevalence, risk factors and underdiagnosis of asthma and wheezing in 
adults 40 years and older: A population-based study. J Asthma. 2015;(May):1–
	
The Burden of Chronic Respiratory Disease in the Western Cape 
Part B: Literature review 
14 
8. https://doi.org/10.3109/02770903.2015.1010733 
19.  Moreira GL, Manzano BM, Gazzotti MR, Nascimento OA, Perez-Padilla R, 
Menezes AMB, et al. PLATINO, a nine-year follow-up study of COPD in the 
city of São Paulo, Brazil: the problem of underdiagnosis. J Bras Pneumol. 
2013;40(1):30–7. https://doi.org/10.1590/s1806-37132014000100005 
20.  Lamprecht B, Soriano JB, Studnicka M, Kaiser B, Vanfleteren LE, Gnatiuc L, 
et al. Determinants of Underdiagnosis of COPD in National and International 
Surveys. Chest. 2015;148(4):971–85. https://doi.org/10.1378/chest.14-2535 
21.  Casas Herrera A, Montes de Oca M, López Varela MV, Aguirre C, Schiavi E, 
Jardim JR. COPD Underdiagnosis and Misdiagnosis in a High-Risk Primary 
Care Population in Four Latin American Countries. A Key to Enhance Disease 
Diagnosis: The PUMA Study. PLoS One. 2016;11(14):e0152266. 
https://doi.org/10.1371/journal.pone.0152266 
22.  Martinez CH, Mannino DM, Jaimes FA, Curtis JL, Han MK, Hansel NN, et al. 
Undiagnosed Obstructive Lung Disease in the United States: Associated 
Factors and Long-term Mortality. Ann Am Thorac Soc. 2015;12(12):1788–95. 
https://doi.org/10.1513/annalsats.201506-388oc 
23.  Llordés M, Jaén A, Almagro P, Heredia JL, Morera J, Soriano JB, et al. 
Prevalence, Risk Factors and Diagnostic Accuracy of COPD Among Smokers 
in Primary Care. COPD. 2015;12(4):404–12. 
https://doi.org/10.3109/15412555.2014.974736 
24.  Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prognosis of 
asymptomatic and symptomatic, undiagnosed COPD in the general population 
in Denmark: a prospective cohort study. Lancet Respir Med. 2017;5:426–34. 
https://doi.org/10.1016/s2213-2600(17)30119-4 
25.  Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, et al. 
Prevalence and underdiagnosis of chronic obstructive pulmonary disease 
among patients at risk in primary care. Can Med Assoc J. 2010;182(7):673–8. 
https://doi.org/10.1503/cmaj.091784 
26.  Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to 
tobacco dependence of chronic obstructive pulmonary disease in a nationally 
representative population sample. Thorax. 2006;61:1043–7. 
https://doi.org/10.1136/thx.2006.064410 
27.  Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, et 
	
The Burden of Chronic Respiratory Disease in the Western Cape 
Part B: Literature review 
15 
al. Opportunities to diagnose chronic obstructive pulmonary disease in routine 
care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 
2014;2:267–76. https://doi.org/10.1016/s2213-2600(14)70008-6 
28.  Jardim JR, Stirbulov R, Moreno D, Zabert G, Lopez-Varela M V, Montes de 
Oca M. Respiratory medication use in primary care among COPD subjects in 
four Latin American countries. Int J Tuberc Lung Dis. 2017;21(4):458–65.  
29.  Ingebrigtsen TS, Marott JL, Vestbo J, Hallas J, Nordestgaard BG, Dahl M, et 
al. Characteristics of Undertreatment in COPD in the General Population. 
Chest. 2013;144(6):1811–8. https://doi.org/10.1378/chest.13-0453 
30.  Make B, Dutro MP, Paulose-Ram R, Mapel DW. Undertreatment of COPD: a 
retrospective analysis of US managed care and Medicare patients. Int J COPD. 
2012;7:1–9. https://doi.org/10.2147/copd.s27032 
31.  Sastre J, Fabbri LM, Price D, Wahn HU, Bousquet J, Fish JE, et al. Insights, 
attitudes, and perceptions about asthma and its treatment: a multinational 
survey of patients from Europe and Canada. World Allergy Organ J. 
2016;9(13). http://dx.doi.org/10.1186/s40413-016-0105-4 
32.  Enright PL, McClelland RL, Newman AB, Gottlieb DJ, Lebowitz MD. 
Underdiagnosis and Undertreatment of Asthma in the Elderly. Chest. 
1999;116:603–13. https://doi.org/10.1378/chest.116.3.603 
33.  Nishimura K, Sato S, Tsukino M, Hajiro T, Ikeda A, Koyama H, et al. Effect of 
exacerbations on health status in subjects with chronic obstructive pulmonary 
disease. Health Qual Life Outcomes. 2009;7(69):1-8. 
https://doi.org/10.1186/1477-7525-7-69  
34.  Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. 
Effect of exacerbations on quality of life in patients with chronic obstructive 
pulmonary disease: a 2 year follow up study. Thorax. 2004;59:387–95. 
https://doi.org/10.1136/thx.2003.008730 
35.  Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al. 
Health-related quality of life in patients by COPD severity within primary care 
in Europe. Respir Med. 2011;105:57–66. 
https://doi.org/10.1016/j.rmed.2010.09.004 
36.  Zamzam MA, Azab NY, Wahsh RA El, Ragab AZ, Allam EM. Quality of life 
in COPD patients. Egypt J Chest Dis Tuberc. 2012;61:281–9. 
http://dx.doi.org/10.1016/j.ejcdt.2012.08.012 
	
The Burden of Chronic Respiratory Disease in the Western Cape 
Part B: Literature review 
16 
37.  Taponen S, Lehtimäki L, Karvala K, Luukkonen R, Uitti J. Correlates of 
employment status in individuals with asthma: a cross-sectional survey. J 
Occup Med Toxicol. 2017;12(19):1–7. https://doi.org/10.1186/s12995-017-
0165-6 
38.  Løkke A, Hilberg O, Tønnesen P, Ibsen R, Kjellberg J, Jennum P. Direct and 
indirect economic and health consequences of COPD in Denmark: a national 
register-based study: 1998 – 2010. BMJ Open. 2014;4(e004069). 
https://doi.org/10.3109/15412555.2013.839647 
39.  Chaker L, Falla A, Van Der Lee SJ, Muka T, Imo D, Jaspers L, et al. The 
global impact of non-communicable diseases on macro-economic productivity: 
a systematic review. Eur J Epidemiol. 2015;30:357–95. 
http://dx.doi.org/10.1007/s10654-015-0026-5 
40.  World Health Organisation. WHO strategy for prevention and control of 
chronic respiratory diseases. Geneva: WHO, 2002. 





































*This journal manuscript meets the requirements in the Author Guidelines for the 
South African Medical Journal, included as an appendix in Part D of this dissertation. 
Spacing of text has been adapted to align with the other sections of the dissertation. 
 
The Burden of Chronic Respiratory Disease in the Western Cape  
Part C: Manuscript 
2 
The Burden of Chronic Respiratory Disease in the Western Cape 
 
Emma Claire Carkeek1* 
MBChB (UCT), Dip Obst (SA) 
 
1Division of Epidemiology and Biostatistics, School of Public Health & Family 
Medicine, University of Cape Town, Cape Town, South Africa 
 
Address: Division of Epidemiology and Biostatistics 
School of Public Health & Family Medicine 
University of Cape Town, Falmouth Building 
Anzio Road, Observatory 
Cape Town, South Africa 
7925 
  
Email:  emma.carkeek@uct.ac.za 
 



















Keywords: Chronic respiratory disease, COPD, asthma, burden, quality of 
life, treatment, Western Cape  
 
Target journal: South African Medical Journal 
 
(Abstract word count: 409) † 
(Manuscript word count: 4 040) ‡ 
 
 
*As per the Master of Public Health dissertation guidelines, co-authors are not listed on the journal ready 
manuscript. The contribution of supervisors and other collaborators is listed in the acknowledgements section at 
the start of the dissertation. 
†Abstract word limit for the South African Medical Journal is 400 words. 
‡Manuscript word limit for the South African Medical Journal is 4 000 words. 
  
The Burden of Chronic Respiratory Disease in the Western Cape  
Part C: Manuscript 
3 
C1: ABSTRACT  
 
Background: Chronic respiratory disease (CRD) is underdiagnosed, undertreated and 
poorly controlled, especially in low- and middle-income countries. Poor control is 
associated with poorer quality of life, increased burden on the healthcare system, and 
negative economic impact due to loss of productivity. Limited data are available on 
the burden of CRD in South Africa. 
 
Objectives: To describe the symptomatic burden of disease and levels of treatment in 
adults with CRD attending primary healthcare facilities in the Western Cape, and to 
identify predictors of quality of life and receipt of treatment in this population. 
 
Methods: We enrolled 1 157 patients with CRD attending 38 primary care clinics in 
the Western Cape, recruited as part of a randomised controlled trial. Secondary 
endpoints in the trial included quality of life, assessed using the St George’s 
Respiratory Questionnaire (SGRQ), and receipt of treatment, measured using self-
report. Linear regression models were used to identify predictors of quality of life and 
logistic regression models to identify predictors of treatment. 
 
Results: Among patients with CRD, the mean SGRQ symptoms score, on a scale of 0 
to 100, was 55.3 and activity score 69.0. Despite being symptomatic, 40% of patients 
were not receiving treatment for CRD. A higher (worse) SGRQ symptoms score was 
associated with male sex (p<0.001), positive screen for depression (p=0.001), 
previous tuberculosis (p<0.001), previous smoking (p=0.012), higher (worse) SGRQ 
activity score (p<0.001) and current receipt of treatment for CRD (p<0.001). Greater 
activity limitation was associated with unemployment (p=0.027), diabetes (p=0.032), 
positive screen for depression (p<0.001), higher SGRQ symptoms score (p<0.001), 
recent hospital admission (p=0.004) and receiving treatment for CRD (p=0.013). 
Older patients (p=0.002) and patients with a higher symptoms score (p=0.007) or 
greater activity limitation (p=0.006) were more likely, and those who screened 
positive for depression, (p<0.001), were current smokers (p=0.040), or had recent 
clinic visits (p=0.009) or hospital admissions (p=0.011) were less likely to be 
receiving treatment for CRDs.  
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Conclusion: Our results confirm a high burden of symptoms and activity limitation, 
and of undertreatment, possibly contributed to by under-recognition of respiratory 
disease  among patients attending primary care clinics in the Western Cape. 
Depression, a history of previous tuberculosis and unemployment are common 
features in such patients. Potential interventions are to introduce a systematic 
approach to CRD diagnosis in primary care clinics that includes screening for 
depression, improving availability of essential drugs for the management of CRDs, 
and preventive strategies such as more effective tuberculosis control, and support and 
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The World Health Organisation (WHO) defines chronic respiratory disease (CRD) as 
‘chronic diseases of the airways and other structures of the lung’, of which asthma 
and chronic obstructive pulmonary disease (COPD) comprises the majority.[1] CRD is 
responsible for significant morbidity and mortality worldwide.[2] In 2015, the 
estimated global prevalence of asthma was 358 million and 174 million for COPD.[3] 
Between 2005 and 2015, the prevalence of COPD increased by 17%, and asthma by 
9.5%.[3] 
 
Although asthma and COPD cannot be cured, they can be controlled using 
appropriate medications. Poorly controlled CRD is associated with significantly 
poorer quality of life and mortality for patients, an increased burden on the healthcare 
system due to increased utilisation of resources, and a negative economic impact due 
to loss of productivity and premature retirement from the workforce.[4],[5] CRD is 
underdiagnosed, undertreated and poorly controlled, especially in low- and middle-
income countries.[2],[6],[7] Improving control of CRD would result in improved quality 
of life for patients and a reduced burden on the healthcare system and economy. 
 
With the global increase in burden, the WHO has developed a strategy for the 
prevention and control of CRD, one of the objectives being ‘better surveillance to 
map the magnitude of chronic respiratory diseases and analyse their determinants with 
particular reference to poor and disadvantaged populations, and to monitor future 
trends’.[8] Limited data are available on the burden of CRD in South Africa and 
particularly on the availability and efficacy of measures to control them at healthcare 
provider level.[2],[7] Such data are essential if appropriate measures are to be put in 
place to address these needs. 
 
This study aimed to describe the symptomatic burden of disease and levels of 
treatment in adults with CRD attending primary healthcare facilities in the Western 
Cape, and to identify predictors of both the quality of life and receipt of treatment in 
this population. 
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The study population consisted of adults accessing healthcare at primary care level 
facilities in the Eden and Overberg Districts of the Western Cape, who were enrolled 
in a pragmatic cluster randomised controlled trial designed to test the effectiveness of 
the Primary Care 101 (PC101) programme in improving management of non-
communicable diseases at a primary healthcare level.[6] The trial recruited four adult 
patient cohorts; attendees with hypertension, diabetes, CRD and/or a positive screen 
for depression. The study population for the current study was limited to participants 
enrolled in the CRD cohort in both the intervention and control arms of the PC101 
trial. The methods of the trial have been reported elsewhere. [6] 
 
Participants were recruited from 38 clinics in the Eden and Overberg Districts. 
Together, these districts have a population of approximately 800 000 with the 
majority of those employed working in commercial services. For clinics to be 
included, they needed to provide services for non-communicable diseases at least 5 
days a week and to report more than 10 000 clinic visits per year. As only 33 of the 
124 clinics in the Eden district met these criteria, an additional 5 clinics from adjacent 
sub-districts in the Overberg district were included to ensure an adequate sample size. 
The clinics were mainly in medium-sized towns and rural areas, and were 
predominantly nurse-led with doctor support ranging from daily to sessional. The 
populations served by these clinics are generally of poor socioeconomic status with 
high levels of unemployment. 
 
Patients were eligible for recruitment if they reported being on treatment for asthma, 
chronic bronchitis or emphysema, or if they reported a cough or difficulty breathing 
for more than 2 weeks and were not on treatment for tuberculosis (TB) in the past 3 
months. They also needed to be at least 18 years of age, able to actively participate in 
an interviewer-administered questionnaire, likely to stay in the same area for the 
duration of the trial and provide written consent to participate in the study. Patients 
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were approached in clinic waiting areas and, those that were eligible and provided 




Immediately after enrollment, a trained fieldworker conducted a baseline interview 
with each participant, using a standardised structured questionnaire which was 
completed in the participant’s language of choice (English, Afrikaans or isiXhosa). 
Questions related to basic demographics, socioeconomic status, medical history, 
smoking history, current state of health, severity of symptoms and levels of healthcare 
utilisation. Baseline anthropometric measurements were taken, including blood 
pressure, weight, height and waist circumference. The fieldworker entered all 
questionnaire responses and measurements into an electronic hand-held device at the 
time of the interview. Fieldworkers then collected all prescription data by 
photocopying prescription charts for the year preceding the interview. A medically 
qualified trial manager reviewed this data and was responsible for identifying 
medications used to treat CRD at the time of the interview. 
 
The St George’s Respiratory Questionnaire (SGRQ), designed to measure respiratory 
disease-specific health status in patients with asthma and COPD, was used to assess 
quality of life.[9] This is a widely accepted tool with validated translations in many 
languages including South African English and Afrikaans. It contains three domains; 
including a ‘symptoms’ domain that assesses frequency of symptoms in order to 
capture the patient’s perception of their current respiratory problems, and an ‘activity’ 
domain that interrogates the impact of respiratory disease on daily physical activity. 
For each domain, a score between 0 and 100 is calculated, with higher scores 
representing worse health status, and a difference in score of 4 units or more being 
regarded as clinically significant.[10],[11] The third domain; ‘impacts’ was not included 
and thus the usual metric of SGRQ total score was not calculated. As there is no 
validated translation of this questionnaire in isiXhosa, participants who completed the 
interview in isiXhosa (8.5%) did not complete a SGRQ questionnaire. 
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Receipt of treatment was measured using self-report, with participants being classified 
as receiving treatment if they reported taking medications for asthma, chronic 




Statistical analyses were performed to identify participant characteristics associated 
with quality of life and receipt of treatment. 
 
Differences in characteristics between participants receiving and not receiving 
treatment were tested using univariate logistic regression models. Each model 
included only the participant characteristic as the explanatory variable, with the 
outcome being treatment status, and was adjusted for an effect due to the cluster 
sampling technique used. 
 
Multiple linear regression models were used to identify predictors of quality of life - 
respiratory symptoms and activity limitation. These were measured using the SGRQ 
symptoms and activity domain scores respectively. A backward selection approach 
was used, with all covariates initially being included in the model. Covariates with a 
p-value of ≥ 0.2 were then removed in a step-wise approach and the model repeatedly 
re-fitted until a final model was identified including only statistically significant 
covariates. Using a forward selection approach, each of the dropped covariates was 
then individually added back into the final model to ensure no significant predictors 
were omitted. The analysis was repeated excluding clinical covariates, which may 
have masked the effects of more upstream covariates. Analysis was first performed on 
the full cohort and then stratified according to treatment status. 
 
Multiple logistic regression models were used to identify predictors of treatment, built 
using the same approach outlined above and repeated excluding clinical covariates. A 
sensitivity analysis was also performed excluding participants who reported receiving 
treatment but whose prescription charts showed no evidence of treatment. 
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All models were adjusted for the cluster sampling method used in the trial design, but 
not for trial arm as only baseline data were analysed. A level of significance of 0.05 
was used for all analyses. Stata 13.0 (Stata Corporation, College Station, Texas) was 
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A total of 1 157 participants were included in the analysis. Participant baseline 
characteristics and the differences between those receiving and those not 
receiving treatment are shown in Table 1. The majority of participants were female 
(70.8%) and Afrikaans-speaking (83.4%), with a mean age of 51.2 years. The 
majority had not completed secondary school education (59.6%), were unemployed 
(79.6%) and receiving a welfare grant (59.9%), and reported a median monthly 
income of ZAR 1 140. Forty-four per cent were obese and comorbidity was common 
with 66.6% reporting a previous diagnosis of hypertension, 41.3% reporting a 
previous diagnosis of cardiovascular disease and 64.8% screened positive for 
depression at the time of interview. Most were either previous (25.5%) or current 
(39.9%) smokers and 18.3% reported previous TB. The mean SGRQ score for the 
symptoms domain was 55.3, and for the activity domain, 69.0. 
 
Forty per cent (458 participants) were not on treatment for CRD, despite being 
symptomatic. On univariate analysis (Table 1), participants receiving treatment were 
more likely to be older (p<0.001), unemployed (p=0.001), receiving a grant 
The Burden of Chronic Respiratory Disease in the Western Cape  
Part C: Manuscript 
10 
(p=0.010), obese (p=0.005) and to have a history of TB (p=0.039). Treatment was 
also more likely with increased symptoms (p<0.001) and activity limitation 
(p<0.001), as well as higher levels of smoking amongst previous and current smokers 
(p=0.003). Participants were less likely to be on treatment if they were more educated 
(p=0.041), had received a previous diagnosis of depression (p=0.011) or screened 
positive for depression at the time of interview (p<0.001). Although 60% of 
participants reported receipt of treatment, review of prescription charts showed that 
only 51% had been prescribed medications for CRD (Table 2). Amongst all 
participants, only 48% had been prescribed a selective β2-agonist and 34% an inhaled 
corticosteroid. 
 
Results of linear regression analysis to identify predictors of respiratory 
symptoms are shown in Table 3A. More symptoms were associated with male sex 
(p<0.001), a positive depression screen (p=0.001), previous TB (p<0.001), being a 
previous smoker (p=0.012), a higher SGRQ activity domain score (p<0.001) and 
receiving treatment for CRD (p<0.001). Diabetes was associated with fewer 
symptoms (p=0.017). When clinical characteristics were removed from the model, 
results were similar with strengthened associations seen between respiratory 
symptoms and depression, previous TB and smoking history. However, the 
association between symptoms and diabetes became insignificant. Similar results 
were reported when analysis was stratified according to treatment status, but the 
association between symptoms and smoking status became insignificant (Tables 3B 
and 3C). Amongst participants not receiving treatment, the association with diabetes 
and previous TB also became insignificant.  
 
Results of linear regression analysis to identify predictors of activity limitation 
are shown in Table 4A. Greater limitation was positively associated with 
unemployment (p=0.027), diabetes (p=0.032), a positive depression screen (p<0.001), 
higher SGRQ symptoms scores (p<0.001), being admitted to hospital in the previous 
3 months (p=0.004) and receipt of treatment for CRD (p=0.013). Male sex was 
associated with less activity limitation (p=0.011). When clinical characteristics were 
removed from the model, strengthened associations were seen with unemployment 
and depression. Greater  limitation was also associated with cardiovascular disease 
(p=0.038) and previous TB (p=0.046). However, the association with sex and diabetes 
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became insignificant. When analysis was stratified according to treatment status, 
greater limitation remained more likely amongst participants with symptoms of 
depression and higher SGRQ symptoms scores (Tables 4B and 4C). 
 
Results of logistic regression analysis to identify predictors of receiving any 
treatment for CRD are shown in Table 5. Participants were more likely to be on 
treatment if they were older (OR=1.02; p=0.002), more symptomatic (OR=1.01; 
p=0.007) or had higher levels of activity limitation due to their respiratory condition 
(OR=1.01; p=0.006). Treatment was less likely in participants who screened positive 
for depression (OR=0.42; p<0.001), were current smokers (OR=0.68; p=0.040), had > 
3 clinic visits in the previous 3 months (OR=0.63; p=0.009) or had been admitted to 
hospital in the previous 3 months (OR=0.46; p=0.011). When clinical variables were 
removed from the model, the associations with age and a positive depression screen 
remained similar. However, treatment was also more likely in participants who were 
unemployed (OR=1.48; p=0.026), obese (OR=1.54; p<0.001) or had previous TB 
(OR=1.77; p=0.004), and less likely in those who were isiXhosa- versus Afrikaans-
speaking (OR=0.64; p=0.025). A sensitivity analysis excluding the 126 people who 
reported receiving treatment but whose prescription charts provided no evidence of 
treatment showed similar results, however the association between treatment and 
smoking status became insignificant. 
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Table 1. Participants’ baseline characteristics  
 
     All participants On treatment Not on treatment  
Characteristics    N=1 157   N=699  N=458   p-value* 
 
Age (years), mean (SD)   51.2 (12.6) 52.7 (11.7) 48.8 (13.5)  <0.001 
 
Sex, %            0.554 
Female     70.8  71.5  69.7  
 
Language , %           0.274 
Afrikaans    83.4  85.4  80.4  
isiXhosa    8.5  6.3  11.8  
English     8.1  8.3  7.9  
 
Highest education, %†          0. 041 
None     9.6  11.0  7.3  
Primary    50.0  51.0  48.4  
Secondary    39.1  36.8  42.5  
Tertiary    1.4  1.1  1.7   
 
Unemployed, %†    79.6  83.0  74.3   0.001 
       
Receiving welfare grant, %†   59.9  64.0  53.5   0.010  
 
Total monthly income (ZAR), median (IQR) 1 140 (0 - 1140) 1 140 (0 - 1140) 1 080 (0 - 1140)  0.239 
     n=1 151  n=695  n=456 
 
History of hypertension, %†   66.6  68.7  63.3   0.170  
 
History of diabetes, %†   28.2  29.9  25.5   0.257 
      
History of depression, %†   31.5  27.9  37.1   0.011 
    
Positive depression screen‡, %  64.8  60.7  71.2   <0.001  
 
Known cardiovascular disease§, %  41.3  43.1  38.7   0.375 
 
Obese¶, %†    44.0  47.5  38.6   0.005 
   
Previous tuberculosis, %†    18.3  20.4  15.1   0.039 
 
On antiretroviral therapy, %†   3.4  2.7  4.4   0.074 
 
Smoking status, %†           0.326 
Never smoker    34.6  33.9  35.8  
Previous smoker    25.5  29.4  19.6  
Current smoker    39.9  36.8  44.7  
      
Smoking pack-year history||, mean (SD) 12.0 (13.4) 13.2 (14.7) 10.2 (11.0)  0.003 
     n=581  n=353  n=228 
 
SGRQ symptom score**, mean (SD)  55.3 (25.2) 58.5 (25.2) 49.7 (24.3)  <0.001 
     n=833  n=534  n=299  
 
SGRQ activity score**, mean (SD)  69.0 (26.0) 72.8 (24.6) 62.7 (27.0)  <0.001 
     n=1 054  n=651  n=403 
___________________________________________________________________________________________________________ 
 
SD = standard deviation; ZAR = South African rands; IQR = interquartile range; BMI = body mass index; SGRQ = St George’s 
Respiratory Questionnaire 
*p-values from logistic regression models adjusted for cluster sampling method 
†Percentage of available data. Lowest n for these parameters was 1036. 
‡Score of ten or more on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) 
§History of angina, heart attack or stroke 
¶ BMI ≥ 30kg/m2 
||For current and previous smokers 
**Participants completing the interview in isiXhosa were excluded from the SGRQ due to no tested translated isiXhosa version of the 
questionnaire. The SGRQ symptom and activity scores therefore apply to Afrikaans and English speakers only. 
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Table 2. Treatment amongst all participants (according to prescription charts) 
     
Medication prescribed  N=1 157______ 
 
None, n (%)   567 (49.0)   
Selective beta-agonist, n (%)  558 (48.2)   
Inhaled corticosteroids, n (%)  388 (33.5)   
Theophylline, n (%)  121 (10.5)   
Ipratropium bromide, n (%)  91 (7.9) 
	
	
The Burden of Chronic Respiratory Disease in the Western Cape  
Part C: Manuscript 
14 
Table 3A. Predictors of respiratory symptoms (all participants) 
 
    SGRQ symptom score:   SGRQ symptom score:     SGRQ symptom score:   
Outcome    Full model (N=698)   Limited model (N=813)    Excluding clinical covariates* (N=821)_________ 
 
Explanatory variable  Coef. 95% CI  p-value  Coef. 95% CI  p-value   Coef. 95% CI  p-value___________ 
 
Age (years)   0.08 -0.09 – 0.24 0.353 
Sex (male vs female)  5.54 1.80 – 9.28 0.005  5.42 2.58 – 8.25 < 0.001   4.34 1.21 – 7.47 0.008 
Language 
Afrikaans (reference)  Ref  
isiXhosa†     
English   -1.71 -10.10 – 6.68 0.682 
Highest education      0.698‡    
None (reference)  Ref    
Primary   -1.83 -7.06 – 3.40 0.482  
Secondary   -1.94 -6.66 – 2.78 0.411 
Tertiary   3.33 -11.87 – 18.53 0.660 
Unemployed   1.51 -3.77 – 6.79 0.566     
Receiving welfare grant  -4.81 -7.90 – -1.71 0.003 
Total monthly income (ZAR)  1.39 -0.72 – 3.50 0.189 
History of hypertension  -2.48 -5.68 – 0.72 0.125 
History of diabetes   -3.50 -7.32 – 0.32 0.071  -4.28 -7.76 – -0.79 0.017   
History of depression  1.95 -2.02 – 5.92 0.327 
Positive depression screen§  6.98 3.21 – 10.74 0.001  6.29 2.93 – 9.66 0.001   11.92 7.93 – 15.92 < 0.001  
Known cardiovascular disease¶ 2.40 -1.33 – 6.14 0.201 
Obese||    0.70 -3.07 – 4.46 0.710  
Previous tuberculosis  7.44 3.47 – 11.42 0.001  7.59 4.53 – 10.64 < 0.001   10.40 6.58 – 14.21 < 0.001   
On antiretroviral therapy  1.53 -7.87 – 10.92 0.744 
Smoking status       
Never smoker (reference)  Ref       
Previous smoker  5.42 0.87 – 9.97 0.021  4.84 1.11 – 8.57 0.012   7.03 2.47 – 11.59 0.003   
Current smoker   4.65 0.05 – 9.26 0.048  3.35 -0.47 – 7.18 0.084   3.67 -0.59 – 7.93 0.089 
SGRQ activity score  0.47 0.39 – 0.55 <0.001  0.47 0.40 – 0.53 < 0.001   Excluded from analysis   
Clinic visits**   -0.37 -3.57 – 2.84 0.818 
Hospital admissions††  3.90 -3.24 – 11.04 0.275 
On CRD treatment   8.00 4.11 – 11.88 <0.001  7.17 3.92 – 10.42 < 0.001   Excluded from analysis  
_________________________________________________________________________________________________________________________________________________________________	
SGRQ = St George’s Respiratory Questionnaire; Coef = coefficient; CI = confidence interval; BMI = body mass index; ZAR = South African rands; CRD = chronic respiratory disease 
*Model adjusted for all covariates in full model, excluding SGRQ activity score, clinic visits, hospital admissions and treatment status. 
†Participants completing the interview in isiXhosa were excluded from the SGRQ due to no tested translated isiXhosa version of the questionnaire. Analyses including SGRQ are therefore restricted to 
English and Afrikaans speakers only. 
‡Test for trend 
§Score of ten or more on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) 
¶ History of angina, heart attack or stroke 
||BMI ≥ 30kg/m2  
**More than 3 versus ≤ 3 clinic visits in the previous 3 months 
††Admitted to hospital in the previous 3 months (yes vs no)  
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Table 3B. Predictors of respiratory symptoms amongst participants on treatment 
 
    SGRQ symptom score:   SGRQ symptom score:     SGRQ symptom score:   
Outcome    Full model (N=448)   Limited model (N=530)    Excluding clinical covariates* (N=527)_________ 
 
Explanatory variable  Coef. 95% CI  p-value  Coef. 95% CI  p-value   Coef. 95% CI  p-value___________ 
 
Age (years)   0.02 -0.21 – 0.25 0.860 
Sex (male vs female)  5.31 1.18 – 9.44 0.013  4.94 1.33 – 8.56 0.009   
Language 
Afrikaans (reference)  Ref  
isiXhosa†     
English   -5.39 -14.93 – 4.15 0.259 
Highest education      0.531‡ 
None (reference)  Ref    
Primary   -3.94 -10.10 – 2.23 0.203 
Secondary   -3.64 -9.76 – 2.48 0.235 
Tertiary   4.63 -14.96 – 24.23 0.635 
Unemployed   1.22 -5.51 – 7.95 0.716     
Receiving welfare grant  -4.19 -9.91 – 1.53 0.147 
Total monthly income (ZAR)  -0.76 -3.98 – 2.45 0.633 
History of hypertension  -3.62 -7.49 – 0.23 0.065        -5.33 -9.99 – -0.67 0.026   
History of diabetes   -4.37 -9.48 – 0.75 0.092  -4.99 -9.54 – -0.44 0.033    
History of depression  3.40 -2.03 – 8.83 0.212    
Positive depression screen§  8.18 3.63 – 12.73 0.001  7.08 2.82 – 11.34 0.002   12.89 8.13 – 17.64 < 0.001   
Known cardiovascular disease¶ 1.94 -2.51 – 6.39 0.383 
Obese||    -0.25 -4.65 – 4.14 0.907  
Previous tuberculosis  8.68 3.69 – 13.67 0.001  10.38 6.19 – 14.57 < 0.001   10.18 4.88 – 15.48 < 0.001 
On antiretroviral therapy  3.68 -6.56 – 13.91 0.471 
Smoking status       
Never smoker (reference)  Ref 
Previous smoker  2.71 -2.67 – 8.09 0.314        5.56 0.01 – 11.12 0.049   
Current smoker   2.04 -3.01 – 7.10 0.418        4.66 -0.26 – 9.57 0.063   
SGRQ activity score  0.51 0.42 – 0.59 <0.001  0.50 0.41 – 0.59 < 0.001   Excluded from analysis 
Clinic visits**   -0.82 -5.22 – 3.58 0.707 
Hospital admissions††  4.82 -4.75 – 14.39 0.314 
On CRD treatment   8.54 2.96 – 14.12 0.004  7.10 2.00 – 12.20 0.008   Excluded from analysis 
_________________________________________________________________________________________________________________________________________________________________
SGRQ = St George’s Respiratory Questionnaire; Coef = coefficient; CI = confidence interval; BMI = body mass index; ZAR = South African rands; CRD = chronic respiratory disease 
*Model adjusted for all covariates in full model, excluding SGRQ activity score, clinic visits, hospital admissions and treatment status. 
†Participants completing the interview in isiXhosa were excluded from the SGRQ due to no tested translated isiXhosa version of the questionnaire. Analyses including SGRQ are therefore restricted to 
English and Afrikaans speakers only. 
‡Test for trend 
§Score of ten or more on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) 
¶ History of angina, heart attack or stroke 
||BMI ≥ 30kg/m2  
**More than 3 versus ≤ 3 clinic visits in the previous 3 months 
††Admitted to hospital in the previous 3 months (yes vs no) 
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Table 3C. Predictors of respiratory symptoms amongst participants not on treatment 
 
    SGRQ symptom score:   SGRQ symptom score:     SGRQ symptom score:   
Outcome    Full model (N=250)   Limited model (N=295)    Excluding clinical covariates* (N=294)_________ 
 
Explanatory variable  Coef. 95% CI  p-value  Coef. 95% CI  p-value   Coef. 95% CI  p-value___________ 
                                      
Age (years)   0.13 -0.11 – 0.37 0.276 
Sex (male vs female)  5.80 -1.68 – 13.27 0.125  7.44 1.39 – 13.50 0.017   
Language 
Afrikaans (reference)  Ref  
isiXhosa† 
English   6.64 -3.95 – 17.23 0.212 
Highest education      0.972‡    
None (reference)  Ref    
Primary   3.24 -11.56 – 18.03 0.660 
Secondary   1.69 -13.10 – 16.48 0.818 
Tertiary   4.81 -13.32 – 22.93 0.594 
Unemployed   -0.59 -8.62 – 7.45 0.883     
Receiving welfare grant  -3.12 -8.39 – 2.16 0.239 
Total monthly income (ZAR)  3.53 1.10 – 5.96 0.006 
History of hypertension  -0.16 -6.29 – 5.97 0.959 
History of diabetes   -2.49 -7.89 – 2.91 0.355 
History of depression  -0.55 -6.60 – 5.49 0.853 
Positive depression screen§  4.99 -0.39 – 10.36 0.068  5.00 0.43 – 9.56 0.033   12.94 8.45 – 17.44 < 0.001   
Known cardiovascular disease¶ 2.51 -3.55 – 8.58 0.407 
Obese||    0.75 -5.47 – 6.97 0.808  
Previous tuberculosis  5.81 -0.98 – 12.59 0.091        10.08 4.14 – 16.02 0.001  
On antiretroviral therapy  -1.54 -20.11 – 17.03 0.868 
Smoking status       
Never smoker (reference)  Ref 
Previous smoker  10.16 -0.37 – 20.69 0.058        9.77 1.78 – 17.76 0.018   
Current smoker   8.76 0.66 – 16.85 0.035        5.43 -2.02 – 12.89 0.148  
SGRQ activity score  0.42 0.33 – 0.52 <0.001  0.43 0.35 – 0.51 < 0.001   Excluded from analysis   
Clinic visits**   1.52 -3.16 – 6.19 0.515 
Hospital admissions††  1.66 -8.46 – 11.78 0.742 
On CRD treatment   15.41 -4.30 – 35.11 0.122  13.72 0.05 – 27.39 0.049   Excluded from analysis  
_________________________________________________________________________________________________________________________________________________________________	
SGRQ = St George’s Respiratory Questionnaire; Coef = coefficient; CI = confidence interval; BMI = body mass index; ZAR = South African rands; CRD = chronic respiratory disease 
*Model adjusted for all covariates in full model, excluding SGRQ activity score, clinic visits, hospital admissions and treatment status. 
†Participants completing the interview in isiXhosa were excluded from the SGRQ due to no tested translated isiXhosa version of the questionnaire. Analyses including SGRQ are therefore restricted to 
English and Afrikaans speakers only. 
‡Test for trend 
§Score of ten or more on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) 
¶ History of angina, heart attack or stroke 
||BMI ≥ 30kg/m2  
**More than 3 versus ≤ 3 clinic visits in the previous 3 months 
††Admitted to hospital in the previous 3 months (yes vs no) 
 
	
The Burden of Chronic Respiratory Disease in the Western Cape  
Part C: Manuscript 
17 
Table 4A. Predictors of activity limitation (all participants) 
 
    SGRQ activity score:   SGRQ activity score:     SGRQ activity score:   
Outcome    Full model (N=698)   Limited model (N=824)    Excluding clinical covariates* (N=1053)________ 
 
Explanatory variable  Coef. 95% CI  p-value  Coef. 95% CI  p-value   Coef. 95% CI  p-value___________                       
 
Age (years)   -0.08 -0.28 – 0.11 0.395 
Sex (male vs female)  -4.08 -8.45 – 0.29 0.067  -4.70 -8.28 – -1.12 0.011   
Language 
Afrikaans (reference)  Ref    
isiXhosa†  
English   -2.51 -9.15 – 4.14 0.450 
Highest education      0.333‡   
None (reference)  Ref    
Primary   0.28 -5.51 – 6.06 0.923 
Secondary   -1.28 -6.80 – 4.23 0.640 
Tertiary   -7.04 -19.59 – 5.51 0.263 
Unemployed   5.46 -0.05 – 10.96 0.052  4.53 0.55 – 8.50 0.027   6.85 2.68 – 11.03 0.002 
Receiving welfare grant  -0.33 -4.18 – 3.52 0.863 
Total monthly income (ZAR)  -0.19 -2.27 – 1.89 0.855 
History of hypertension  -0.45 -4.32 – 3.42 0.815 
History of diabetes   3.73 -0.90 – 8.37 0.111  4.29 0.38 – 8.20 0.032    
History of depression  -1.37 -5.50 – 2.77 0.508 
Positive depression screen§  7.93 3.47 – 12.40 0.001  7.61 4.28 – 10.94 < 0.001   11.80 8.28 – 15.31 < 0.001   
Known cardiovascular disease¶ 3.01 -1.20 – 7.23 0.156        5.41 0.33 – 10.49 0.038 
Obese||    2.57 -1.28 – 6.43 0.184  
Previous tuberculosis  0.01 -5.64 – 5.67 0.996        4.78 0.09 – 9.46 0.046  
On antiretroviral therapy  6.60 -5.80 – 19.01 0.288 
Smoking status       
Never smoker (reference)  Ref 
Previous smoker  -2.41 -6.41 – 1.58 0.229 
Current smoker   -1.42 -5.61 – 2.77 0.497 
SGRQ symptom score  0.50 0.42 – 0.58 <0.001  0.49 0.41 – 0.57 < 0.001   Excluded from analysis  
Clinic visits**   -0.73 -4.82 – 3.36 0.720 
Hospital admissions††  4.93 -1.93 – 11.79 0.154  7.83 2.61 – 13.05 0.004   Excluded from analysis 
On CRD treatment   4.16 -0.58 – 7.73 0.024  4.60 1.04 – 8.16 0.013   Excluded from analysis 
_________________________________________________________________________________________________________________________________________________________________	
SGRQ = St George’s Respiratory Questionnaire; Coef = coefficient; CI = confidence interval; BMI = body mass index; ZAR = South African rands; CRD = chronic respiratory disease 
*Model adjusted for all covariates in full model, excluding SGRQ symptom score, clinic visits, hospital admissions and treatment status. 
†Participants completing the interview in isiXhosa were excluded from the SGRQ due to no tested translated isiXhosa version of the questionnaire. Analyses including SGRQ are therefore restricted to 
English and Afrikaans speakers only. 
‡Test for trend 
§Score of ten or more on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) 
¶ History of angina, heart attack or stroke 
||BMI ≥ 30kg/m2  
**More than 3 versus ≤ 3 clinic visits in the previous 3 months 
††Admitted to hospital in the previous 3 months (yes vs no) 
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Table 4B. Predictors of activity limitation amongst participants on treatment 
 
    SGRQ activity score:   SGRQ activity score:     SGRQ activity score:   
Outcome    Full model (N=448)   Limited model (N=533)    Excluding clinical covariates* (N=650)_________ 
 
Explanatory variable  Coef. 95% CI  p-value  Coef. 95% CI  p-value   Coef. 95% CI  p-value___________ 
 
Age (years)   -0.09 -0.34 – 0.16 0.484 
Sex (male vs female)  -3.73 -10.38 – 2.91 0.262  -5.76 -10.76 – -0.76 0.025  
Language 
Afrikaans (reference)  Ref  
isiXhosa† 
English   -0.75 -9.31 – 7.81 0.861 
Highest education      0.845‡    
None (reference)  Ref    
Primary   3.88 -2.01 – 9.77 0.190 
Secondary   2.77 -4.09 – 9.63 0.418 
Tertiary   -5.62 -23.74 – 12.49 0.533 
Unemployed   5.40 -1.98 – 12.78 0.147  5.67 0.44 – 10.90 0.034   7.56 1.82 – 13.30 0.011 
Receiving welfare grant  0.33 -4.23 – 4.88 0.885 
Total monthly income (ZAR)  0.04 -2.95 – 3.04 0.978 
History of hypertension  1.01 -3.58 – 5.61 0.657 
History of diabetes   3.32 -1.45 – 8.10 0.167 
History of depression  -2.74 -8.52 – 3.04 0.343 
Positive depression screen§  5.99 -0.03 – 12.02 0.051  5.80 0.78 – 10.82 0.025   11.55 6.73 – 16.36 < 0.001  
Previous cardiovascular disease¶ 2.37 -3.26 – 8.00 0.399 
Obese||    2.81 -1.33 – 6.96 0.177   
Previous tuberculosis  -3.58 -9.83 – 2.66 0.253 
On antiretroviral therapy  7.65 -1.95 – 17.24 0.115 
Smoking status       
Never smoker (reference)  Ref 
Previous smoker  -2.24 -6.63 – 2.15 0.307 
Current smoker   -0.23 -5.00 – 4.53 0.922 
SGRQ symptom score  0.50 0.41 – 0.60 <0.001  0.48 0.38 – 0.58 < 0.001   Excluded from analysis  
Clinic visits**   -2.02 -6.79 – 2.74 0.395 
Hospital admissions††  1.00 -9.49 – 11.50 0.847 
On CRD treatment   1.72 -4.61 – 8.06 0.585 
_________________________________________________________________________________________________________________________________________________________________	
SGRQ = St George’s Respiratory Questionnaire; Coef = coefficient; CI = confidence interval; BMI = body mass index; ZAR = South African rands; CRD = chronic respiratory disease 
*Model adjusted for all covariates in full model, excluding SGRQ symptom score, clinic visits, hospital admissions and treatment status. 
†Participants completing the interview in isiXhosa were excluded from the SGRQ due to no tested translated isiXhosa version of the questionnaire. Analyses including SGRQ are therefore restricted to 
English and Afrikaans speakers only. 
‡Test for trend 
§Score of ten or more on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) 
¶ History of angina, heart attack or stroke 
||BMI ≥ 30kg/m2  
**More than 3 versus ≤ 3 clinic visits in the previous 3 months 
††Admitted to hospital in the previous 3 months (yes vs no) 
	
The Burden of Chronic Respiratory Disease in the Western Cape  
Part C: Manuscript 
19 
Table 4C. Predictors of activity limitation amongst participants not on treatment 
 
    SGRQ activity score:   SGRQ activity score:     SGRQ activity score:   
Outcome    Full model (N=250)   Limited model (N=299)    Excluding clinical covariates* (N=396)_________ 
 
Explanatory variable  Coef. 95% CI  p-value  Coef. 95% CI  p-value   Coef. 95% CI  p-value___________                                       
 
Age (years)   -0.05 -0.33 – 0.23 0.730 
Sex (male vs female)  -2.41 -10.19 – 5.37 0.534 
Language 
Afrikaans (reference)  Ref    
isiXhosa† 
English   -7.02 -18.48 – 4.43 0.222 
Highest education      0.136‡    
None (reference)  Ref    
Primary   -8.95 -23.28 – 5.37 0.213 
Secondary   -10.64 -24.93 – 3.65 0.140 
Tertiary   -13.80 -29.92 – 2.31 0.091 
Unemployed   5.41 -5.78 – 16.59 0.334     
Receiving welfare grant  -1.42 -8.97 – 6.13 0.705 
Total monthly income (ZAR)  -0.85 -4.39 – 2.70 0.631 
History of hypertension  -3.08 -10.18 – 4.01 0.384 
History of diabetes   6.06 -1.67 – 13.79 0.121  8.28 2.00 – 14.55 0.011      
History of depression  0.79 -4.68 – 6.27 0.770 
Positive depression screen§  12.41 4.95 – 19.88 0.002  11.58 6.06 – 17.10 < 0.001   17.56 11.92 – 23.19 < 0.001   
Previous cardiovascular disease¶  3.52 -1.87 – 8.92 0.194        8.18 2.47 – 13.90 0.006   
Obese||    4.12 -2.96 – 11.21 0.246  
Previous tuberculosis  7.50 -0.80 – 15.80 0.075  7.73 2.36 – 13.11 0.006   11.65 5.84 – 17.46 < 0.001  
On antiretroviral therapy  2.86 -18.30 – 24.01 0.786 
Smoking status       
Never smoker (reference)  Ref 
Previous smoker  -3.22 -11.91 – 5.48 0.458        6.81 0.01 – 13.61 0.050  
Current smoker   -3.61 -10.56 – 3.34 0.299        2.73 -2.21 – 7.67 0.269  
SGRQ symptom score  0.50 0.35 – 0.64 <0.001  0.46 0.33 – 0.60 < 0.001   Excluded from analysis    
Clinic visits**   1.10 -4.93 – 7.12 0.715 
Hospital admissions††  11.17 2.48 – 19.85 0.013  11.33 3.51 – 19.16 0.006   Excluded from analysis  
On CRD treatment   -7.61 -28.20 – 12.98 0.459 
_________________________________________________________________________________________________________________________________________________________________	
SGRQ = St George’s Respiratory Questionnaire; Coef = coefficient; CI = confidence interval; BMI = body mass index; ZAR = South African rands; CRD = chronic respiratory disease 
*Model adjusted for all covariates in full model, excluding SGRQ symptom score, clinic visits, hospital admissions and treatment status. 
†Participants completing the interview in isiXhosa were excluded from the SGRQ due to no tested translated isiXhosa version of the questionnaire. Analyses including SGRQ are therefore restricted to 
English and Afrikaans speakers only. 
‡Test for trend 
§Score of ten or more on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) 
¶ History of angina, heart attack or stroke 
||BMI ≥ 30kg/m2  
**More than 3 versus ≤ 3 clinic visits in the previous 3 months 
††Admitted to hospital in the previous 3 months (yes vs no) 
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Table 5. Predictors of treatment 
 
Outcome    Treatment: full model (N=704)  Treatment: limited model (N=820)  Treatment:  Excluding clinical covariates* (N=1066)____ 
           
Explanatory variable  OR 95% CI  p-value  OR 95% CI  p-value  OR 95% CI  p-value__________________                                      
 
Age (years)   1.02 1.00 – 1.04 0.016  1.02 1.01 – 1.04 0.002  1.02 1.01 – 1.04 0.001 
Sex (male vs female)  0.68 0.45 – 1.05 0.081 
Language 
Afrikaans (reference)  1.00  
isiXhosa†             0.64 0.44 – 0.94 0.025 
English   1.05 0.58 – 1.90 0.879       0.87 0.42 – 1.78 0.696  
Highest education      0.931‡    
None (reference)  1.00    
Primary   0.67 0.39 – 1.16 0.154 
Secondary   0.80 0.40 – 1.61 0.538 
Tertiary   0.97 0.20 – 4.76 0.974 
Unemployed   1.04 0.51 – 2.09 0.917       1.48 1.05 – 2.09 0.026 
Receiving welfare grant  1.37 0.84 – 2.23 0.210 
Total monthly income (ZAR)  0.92 0.66 – 1.27 0.609 
History of hypertension  0.74 0.49 – 1.11 0.141 
History of diabetes   0.93 0.57 – 1.49 0.750 
History of depression  0.75 0.49 – 1.14 0.178 
Positive depression screen§  0.44 0.29 – 0.66 <0.001  0.42 0.28 – 0.63 <0.001  0.64 0.48 – 0.85 0.002  
Known cardiovascular disease¶ 1.08 0.65 – 1.79 0.756 
Obese||    1.34 0.90 – 1.99 0.148       1.54 1.22 – 1.95 < 0.001  
Previous tuberculosis  1.34 0.83 – 2.18 0.234       1.77 1.20 – 2.63 0.004 
On antiretroviral therapy  0.67 0.25 – 1.80 0.423 
Smoking status       
Never smoker (reference)  1.00     1.00 
Previous smoker  1.27 0.74 – 2.18 0.384  1.12 0.67 – 1.87 0.659 
Current smoker   0.73 0.50 – 1.06 0.102  0.68 0.47 – 0.98 0.040  
SGRQ symptom score  1.01 1.00 – 1.02 0.012  1.01 1.00 – 1.02 0.007  Excluded from analysis 
SGRQ activity score  1.01 1.00 – 1.02 0.006  1.01 1.00 – 1.02 0.006  Excluded from analysis 
Clinic visits**   0.68 0.48 – 0.94 0.022  0.63 0.45 – 0.89 0.009  Excluded from analysis 
Hospital admissions††  0.39 0.19 – 0.79 0.010  0.46 0.25 – 0.84 0.011  Excluded from analysis 
_________________________________________________________________________________________________________________________________________________________________	
OR = odds ratio; CI = confidence interval; BMI = body mass index; ZAR = South African rands; SGRQ = St George’s Respiratory Questionnaire 
*Model adjusted for all covariates in full model, excluding SGRQ symptom score, SGRQ activity score, clinic visits and hospital admissions. 
†Participants completing the interview in isiXhosa were excluded from the SGRQ due to no tested translated isiXhosa version of the questionnaire. Analyses including SGRQ are therefore restricted to 
English and Afrikaans speakers only. 
‡Test for trend 
§Score of ten or more on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) 
¶ History of angina, heart attack or stroke 
||BMI ≥ 30kg/m2  
**More than 3 versus ≤ 3 clinic visits in the previous 3 months 
††Admitted to hospital in the previous 3 months (yes vs no) 
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Our study describes the symptomatic burden of disease and levels of treatment, and 
identifies predictors of both the quality of life and receipt of treatment in adults with 
CRD attending primary healthcare facilities in the Western Cape. This population 
showed a significant burden of disease, demonstrated by high mean SGRQ scores. 
According to the SGRQ Manual, healthy individuals without respiratory disease can 
be expected to have a mean total score of 6, with scores of 12, 9 and 2 for the 
symptoms, activity and impacts domains respectively.[9] Ferrer et al assessed 
normative values for a general population in Spain and reported similar mean scores 
for healthy individuals.[12] Various studies have assessed health-related quality of life 
amongst patients with CRD and have correlated SGRQ total and/or domain scores 
with severity of disease based on lung function test results.[13]–[18] To limit the length 
of interviews, we did not assess the SGRQ impacts domain and calculate SGRQ total 
scores. However, it can assumed that these would be slightly lower than the 
symptoms and activity scores as this is a consistent finding across many studies.[9],[12]–
[15],[17] Comparison of our findings indicates that the high SGRQ scores seen in our 
study population correlate with severe to very severe, uncontrolled disease.  
 
We found discordance between results of the two SGRQ domains measured; 
consistently more activity limitation than symptom levels, a feature reported in other 
studies. As in this study, most report higher activity scores especially amongst 
females and patients with severe, uncontrolled disease.[9],[12]–[15],[17] This may reflect 
the fact that this was a working class population where physical activity is demanded 
both at home and, for those who are employed, in the workplace.  
 
Despite this high burden and severity of disease in our population, it appears that 
CRD was underdiagnosed and undertreated. These findings are consistent with reports 
from other countries that show high levels of underdiagnosis ranging from 56.7% to 
78%.[19]–[27] In the Cape Town site of the BOLD study, 81.4% of COPD cases 
confirmed by spirometry were undiagnosed.[19] Similarly, undertreatment of both 
conditions is common, with results from these and other studies ranging from 39% 
and 70%.[28]–[31] Surprisingly, patients with more frequent recent healthcare utilisation 
were less likely to be on treatment. A likely explanation is that these clinic visits and 
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hospital admissions were for reasons other than respiratory disease, a theory 
supported by the high levels of comorbidity in this cohort. This indicates missed 
opportunities for diagnosis and treatment of CRD in both clinic and hospital settings, 
consistent with a retrospective analysis of patients with COPD in the UK which 
showed that in the 5 years preceding the diagnosis of COPD, opportunities for 
diagnosis were missed in 85% of cases.[32] Comorbidity has also been found to be a 
significant predictor of lack of treatment amongst patients undertreated for COPD.[28]  
 
Language, age and obesity were significant predictors of receiving treatment. 
isiXhosa-speaking patients were less likely to be on treatment than Afrikaans-
speaking patients, possibly due to their lower socioeconomic status or level of 
education, or due to a language barrier in clinics where Afrikaans was the usual 
language of communication. Previous studies have shown an association between 
obesity and poorer health-related quality of life in patients with CRD[33]–[35], but 
surprisingly we found no such association. Although females reported significantly 
more activity limitation,  males reported more severe symptoms. Since lung function 
tests were not performed, we cannot assess whether the higher symptoms score in 
males was due to more severe disease, but with preserved activity, or whether they 
over-reported symptoms.  
 
The association between unemployment and higher levels of activity limitation is 
unsurprising as, in a working-class population, limitation of activity is likely to result 
in inability to perform physical work duties, resulting in increased unemployment 
levels. Unemployment was also associated with increased treatment, likely due to the 
higher burden of disease in this group and the fact that those not working have more 
opportunity to seek medical attention. These findings are consistent with previous 
studies which have shown unemployment rates and work disability to be higher 
amongst patients with CRD compared to those without, and higher amongst patients 
with more severe respiratory symptoms versus those with controlled disease.[36]–[39] 
Tottenborg et al found that unemployed patients with COPD were more likely to be 
poorly adherent to medication compared to employed patients, suggesting a 
bidirectional association between unemployment and reduced quality of life.[40] 
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Patients wth diabetes had significantly greater activity limitation but less severe 
symptoms. As the SGRQ symptoms score is more respiratory in nature, i.e. captures 
symptoms of respiratory impairment, the difference in these findings suggests that the 
activity limitation in diabetics is non-respiratory and more likely due to comorbid 
disease. Similarly, the association between cardiovascular disease and greater 
activity limitation is likely to be non-respiratory in nature. 
 
A positive screen for depression was associated with both more severe respiratory 
symptoms and activity limitation. Previous studies have found that CRD increases the 
risk of depression[41],[42], but, as we could not establish temporality, we cannot 
conclude whether depression led to greater impairment in quality of life or vice versa. 
Nonetheless, there is a strong association which remains significant when analysis is 
stratified according to treatment status. Despite this association, patients with 
depression were half as likely to receive CRD treatment, indicative of a significantly 
high burden of CRD amongst this sub-population, with unmet treatment needs. Our 
findings are in keeping with other studies which have found that amongst patients 
with CRD, those with depression have less knowledge about their condition, poorer 
health-related quality of life, more frequent exacerbations and respiratory-related 
hospital admissions and an increased risk of mortality compared to those 
without.[41],[43]–[46] Treatment of depression has also been shown to decrease the risk of 
emergency department visits and hospitalisations due to COPD.[47] 
 
As smoking is a well-recognised contributor to respiratory diseases, we were not 
surprised that ex-smokers in our study had more severe symptoms than never-
smokers. Current smokers were less likely to be on treatment compared to never-
smokers, suggesting that clinicians may possibly view cessation of smoking as the 
first treatment step or that they may be more reluctant to prescribe treatment to 
patients who continue to smoke. Van Eerd et al explored physicians’ attitudes and 
practices towards smokers with COPD. They found that physicians’ treatment of 
smokers was influenced by their inexperience in managing smoking cessation, and 
that continued smoking caused physicians frustration, resulting in negative attitudes 
towards smokers and a reluctance to prescribe effective treatment.[48]  
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Previous tuberculosis was predictive of more severe symptoms and activity 
limitation. Various studies have shown pulmonary tuberculosis (PTB) to be an 
important risk factor for COPD.[49]–[54] Patients with previous PTB have been found to 
have earlier development and progression of COPD, as well as poorer bronchodilator 
response indicating more irreversible disease.[55]–[57] Amongst patients with COPD 
and previous PTB, more extensive parenchymal involvement has also been associated 
with a higher risk of exacerbations.[57] Although both Allwood et al and Lee et al 
found significantly poorer spirometry results amongst those with previous PTB, in 
contrast to our study, neither found a difference in symptoms, SGRQ scores, 
exacerbations or hospitalisations between these groups.[56],[58] Unlike smokers, our 
study found that patients with previous PTB were more likely to receive CRD 
treatment than those without. This may be because they are already within the 
healthcare system and therefore more likely to be diagnosed. Alternatively it may 
support the hypothesis that healthcare worker practice and prejudice contributes 
towards smokers being less likely to receive treatment compared to non-smokers.  
 
Strengths of our study include the large sample size and wide range of demographic 
and socioeconomic characteristics assessed that potentially impact upon CRD and 
their management. However, our study also has limitations. Firstly, patients were 
recruited and analysed using self-report of treatment rather than review of prescription 
charts and may therefore have missed patients who were previously diagnosed but 
were no longer on treatment or not symptomatic at the time of recruitment. However, 
issues like missing prescription charts, duplicate clinic folders or attendance at more 
than one clinic are limitations of the alternative method. Eighteen percent of 
participants recruited by self-report had no evidence of treatment in their prescription 
charts. However, sensitivity analysis showed similar results when this sub-group was 
excluded. A second limitation is that the method did not distinguish asthma from 
COPD and other less common  respiratory conditions. The reasons for this approach 
were that i) trial interventions to confirm diagnoses would have influenced the 
pragmatic nature of the study design, ii) treatments available for these diseases in 
primary healthcare clinics are similar and iii) distinguishing asthma from COPD in 
patients over 40 years is difficult, with up to 20% having features of both. 
Nonetheless, the study provides a perspective on the burden of CRD in general, and 
the impact of various patient characteristics including smoking, TB and other 
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comorbidities. Thirdly, using the presence of prolonged cough or difficulty breathing 
to recruit patients may have resulted in selection bias as these symptoms may, 
uncommonly, be cardiac in origin. Although self-reported cardiovascular disease was 
adjusted for, this did not include diagnosed or undiagnosed cardiac failure. A fourth  
limitation is the homogeneity of the population in terms of language and 
socioeconomic status, therefore limiting observations about the impact of these 
factors in more diverse populations. Lastly, the SGRQ was not completed by 
isiXhosa-speaking participants. Thus, analyses of predictors of quality of life were 





Despite these limitations, our study adds to the limited knowledge of the burden of 
CRD in South Africa, with implications for both clinicians and policymakers. 
Findings indicate a high burden of disease in this population where manual labour is 
common and symptoms therefore more limiting. In keeping with global reports, there 
is major underdiagnosis and undertreatment of CRD in the study population. However 
a difference from global experience is the very high clinical burden in terms of 
symptoms and activity limitation, depression, previous TB and of unemployment. We 
suggest that missed opportunities for diagnosis and treatment in both clinic and 
hospital settings indicate a need for improved screening for CRD amongst patients 
with respiratory symptoms, especially those with identified risk factors or comorbid 
conditions. Our results suggest underdiagnosis of depression; improved mental health 
screening amongst patients with CRD may result in both improved mental health and 
control of respiratory disease. The lack of treatment prescribed to smokers indicates a 
need to explore whether healthcare workers are equipped or reluctant to support 
behaviour change such as smoking cessation and/or provide treatment to smokers who 
are unable or unwilling to quit. Health authorities need to prioritise early recognition 
and treatment for TB to reduce the future burden of COPD, especially in areas with a 
high burden of disease such as the Western Cape. By addressing the above needs, 
earlier diagnosis and treatment of CRD may be achieved, resulting in improved 
quality of life and mental health of patients, greater productivity in the workforce and 
a reduced burden on the healthcare system.  
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Appendix A4. PC101 trial summary 
 
Primary Care 101 Trial Summary 
January 2014 
Title Effectiveness of an integrated care guideline training program on the 
processes and outcomes of non-communicable chronic diseases in 




Primary care management of: 
• diabetes  
• hypertension 
• chronic respiratory disease 
• depression 
Purpose of the 
study 
To evaluate the effectiveness of an integrated guideline-based training 
programme for primary healthcare nurses and doctors (Primary Care 
101) on processes and outcomes of non-communicable chronic 




Pragmatic, two-arm, cluster randomized controlled trial 
Ethics approval University of Cape Town Human Research Ethics Committee and the 




• 38 nurse-led primary care clinics in the Eden district of the 
Western Cape province, South Africa (all clinics service around 
or more than 10 000 attendances per year) 
Patients:  
• Age ≥ 18 years and 
• Planning to reside in the area for the next year and 
• Written consent to participate in the study and 
• Capable of actively engaging in an interviewer-administered 
questionnaire at the time of recruitment and 14 months later 
 
Four cohorts are defined. Patients may fulfil inclusion criteria for more 
than one cohort. Inclusion criteria based on target chronic disease: 
 
Target condition Inclusion criteria 
Hypertension Self-reported hypertension on medication 
Diabetes Self-reported diabetes on medication 
Chronic respiratory 
disease (CRD) 
Self-reported asthma/ COPD/ chronic 
bronchitis/ emphysema on medication OR 
Cough and/or difficult breathing >2 
weeks (not on TB treatment in the past 3 
months) 
Depression CES-D 10 (Centre for Epidemiologic 






• Clinics with less than 9000 attendances in the year preceding 
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randomization 
• Satellite and mobile clinics 
• Clinics providing exclusive antiretroviral treatment services 
Patients: 




Baseline data collection: March 2011 




Target number of 
participants 
Clinics: 38 
Patients:  Estimated 4598 
All calculations are for two-sided tests and are powered at 85%. 
Sample sizes have been inflated by 20% to allow for loss to follow up 
at 1 year. 
 
Chronic disease Cluster size Int Con ICC 
Hypertension 60 0.36 0.25 0.04 
Diabetes 60 0.36 0.25 0.04 
CRD 27 0.25 0.15 0.02 
Depression 60 0.10 0.04 0.04 
 
Interventions Intervention group: 
Primary Care 101: 
• Integrated care guideline 
• Training of existing PALSA PLUS trainers as outreach trainers for 
expanded guideline (one 5 day training) 
• Outreach training of all primary care staff in intervention clinics 
(estimated 6 sessions per clinic)  
• Expanded prescribing provisions for professional nurses (PN) 
trained in Primary Care 101 at intervention clinics for the duration 
of the trial.  
• PALSA PLUS maintenance training to continue in intervention 
group 
Control group: 
PALSA PLUS training and guideline 
Primary outcome 
measures 
Based on target chronic condition. 
Chronic disease Primary outcome 
Hypertension Treatment intensification: 
Increase in dose of antihypertensive medication 
or 
Addition of new antihypertensive or 
Addition of aspirin or 
Addition/ increase in dose of statin 
Diabetes Treatment intensification: 
Increase in dose of oral hypoglycaemic/ insulin 
or 
Addition of new oral hypoglycaemic / insulin or 
Addition/ increase in dose of ACE inhibitor or 
Addition of aspirin or 
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Addition of beta-agonist or 
Addition of ipratropium bromide or 
Addition of oral theophylline or 
Addition/ increase in dose of inhaled 
corticosteroid 
Depression Case detection: 
Started on antidepressant medication or 
Referred for counselling or 





1. Breakdown of treatment intensification by components 
2. Appropriate screening for complications: 
                  Proportion reporting dilated eye exam 
                  Proportion reporting foot exam 
3. Smoking endpoints: 
                  Proportion receiving smoking cessation advice 
                  Readiness to quit smoking 
                  Proportion who quit 
                  Number of units smoked per day 
Intermediate outcomes 
4. Systolic BP 
5. HbA1C  
6. Waist circumference 
7. BMI 
Health outcomes 
8. Health related quality of life (EuroQol 5D, St Georges 




10. Income and changes due to illness 
11. Clinic visits  
12. Admissions 
13. Inpatient days 
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Appendix A5. PC101 trial patient information sheet and consent form 
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1 What is your home language English Afrikaans IsiXhosa 
 
2 Date of interview: 
3 Clinic: 
4 Interviewer Code: 
 
We are conducting a study to evaluate care and risk factors for common chronic diseases, including diabetes, hypertension, 
chest conditions and depression, and we are looking for people with certain criteria to take part. I would like to start by asking 
you a few questions to see whether you qualify to take part in our study.  
 
5 What is your name First name Surname 
6 What is your date of birth  if ≥18 goto 7   if <18 goto 25 
7 Enter sex Male Female  
8 Are you planning to stay in the area for the next year Yes: goto 9 No: goto 18 
9 Are you taking medicine for high blood pressure (hypertension )  Yes: goto 10 No: goto 10 
10 Are you taking medicine for diabetes (‘sugar’) Yes: goto 11 No: goto 11 
11 Are you taking medicine for asthma or chronic bronchitis or emphysema Yes: goto 13 No: goto 12A 
12A Do you have cough or difficult breathing which has lasted for more than 
2 weeks  
Yes: goto 12B No goto 13 
12B Have you been on treatment for TB in the past 3 months 
 [Yes to 12A and No to 12B = yes for question 12] 
Yes: goto 13 No: goto 13 
13 We would like to know how your general well-being has been over the past week. 
I am going to read a list of some of the ways you may have felt or behaved during the last week. Using the showcard, 
please indicate how often you have felt this way during the past week. 
 
Interviewer mark one option on each line 
During the past week... Rarely or none 
of the time 
(less than 1 day) 
Some or little 




amount of time 
(3-4 days) 
All of the 
time 
(5-7 days) 
I was bothered by things that 
usually don’t bother me 
0 1 2 3 
I had trouble keeping my mind on 
what I was doing 
0 1 2 3 
I felt depressed 0 1 2 3 
I felt that everything I did was an 
effort 
0 1 2 3 
I felt hopeful about the future 0 1 2 3 
I felt fearful 0 1 2 3 
My sleep was restless 0 1 2 3 
I was happy 0 1 2 3 
I felt lonely 0 1 2 3 
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Eligible for trial if one or more of the following: 
 
• YES to question 9 (hypertension cohort) 
• YES to question 10 (diabetes cohort) 
• YES to question 11 (respiratory cohort) 
• YES to question 12A AND NO to question 12B (respiratory 
cohort) 
• Score of 10 or more for question 13 (depression cohort) 
 
Yes: eligible for trial: 
goto 14 
No: not eligible for 
trial: goto 18 
Interviewer to fill in enrolment log (paper chart) to keep a record of how many patients in each of the 4 cohorts (hypertension, 
diabetes, chronic respiratory disease and depression risk score ≥10) the clinic has recruited. 
 
14 [eligible for trial, now see if eligible for validation study as well 
with questions 14-17]  
Computer to draw age from previous question  
If ≥35 goto 15. If <35 goto 22 
15 Has a doctor or nurse ever told you that you have or have had any 
of the following: 
15A a heart attack yes no 
15B a stroke yes no 
15C angina (chest pains with exertion/activity) yes no 
 
If YES to any of the 
three (15A, 15B or 15C) 
then eligible for trial 
only: goto 22 
If NO to all three (15A, 
15B and 15C) then 
goto 16 
16 Do you have a South African identity (ID) number  Yes: goto 17 No: eligible for trial 
only: goto 22 
17 Would you be able to give me your ID number today 
 
Yes: eligible for trial and 
validation: do not enter 
ID number at this stage: 
goto 23 
No: eligible for trial 
only: goto 22 
 
18 [not eligible for trial, now assess whether eligible for validation 
study with questions 18-21]  
Computer to draw age from previous question  
If ≥35 goto 19 If <35 goto 25 
19 Has a doctor or nurse ever told you that you have or have had any 
of the following:  
 
19A a heart attack    yes no 
19B a stroke  yes no 
19C angina (chest pains with exertion/activity) yes no 
 
If YES to any of the 
three (19A, 19B or 19C) 
then not eligible for trial 
or study: goto 25 
If NO to all three (19A, 
19B and 19C) goto 20 
20 Do you have a South African identity (ID) number 
 
Yes: goto 21 No: not eligible for trial 
or validation study: 
goto 25 




Yes: eligible for 
validation study only: do 
not enter ID number at 
this stage: goto 24  
 
No: not eligible for trial 
or validation study: 
goto 25 
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[Eligible for trial only]:  
 
You qualify for our study and we would like you to take part.  
 
I will go through the written information with you and if you would like to take part then we will ask you to sign the form 
saying you are willing to participate. 
 
I will then go through the questionnaire with you, check your measurements (blood pressure, weight, height, waist 
circumference and hip measurement), and we may want to take a blood sample. [HbA1c]  
 





[Eligible for trial and validation]: -> AS2 
 
You qualify for our study and we would like you to take part.  
 
I will go through the written information with you and if you would like to take part then we will ask you to sign the form 
saying you are willing to participate. 
 
I will then go through the questionnaire with you, check your measurements (blood pressure, weight, height, waist 
circumference and hip measurement), and we may want to take a blood sample [HbA1c, lipids] 
 






[Eligible for validation only]: -> AS3 
 
You qualify for our shorter questionnaire and we would like you to take part.  
 
I will go through the written information with you and if you would like to take part then we will ask you to sign the form 
saying you are willing to participate. 
 
I will then go through the questionnaire with you, check your measurements (blood pressure, weight, height, waist 
circumference and hip measurement), and we may want to take a blood sample [HbA1c, lipids] 
 




[Not eligible for trial or validation study] 
 
We are looking for people with certain criteria or illnesses to take part in the study. You do not have the criteria we are 
looking for so we will not be able to include you in the study. Your usual care will not be affected by not taking part in our 
study. We would like to thank you very much for answering the questions and for your time today and we wish you well.  
 
[Interviewer to document that the eligibility screen was done and that the patient is not eligible for trial or validation 
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Questionnaire 1:  
 
[Conducted immediately after the eligibility screen for patients eligible to take part in the trial and 
validation study, or just the trial.] 
 
I am now going to go through the questionnaire with you. We will need to take three blood pressure 
readings during the course of the interview, at least two minutes apart. [interviewer to take first blood 
pressure reading now].   
 
I would like to start by asking you a few questions about your past illnesses: 
1       Has a doctor or nurse ever told you that you have or have had any of the following 
1A  high blood pressure (hypertension) Yes No 
1B  heart attack Yes No 
1C stroke Yes No 
1D  angina (chest pains with exertion/activity ) Yes No 
1E  depression Yes No 
1F  TB Yes No 
1G  diabetes (‘sugar’) Yes No 
 
2      I am now going to ask you some questions about smoking 
2A  Do you currently smoke cigarettes daily Yes: goto 2B  No: goto 2E 
2B   How old were you when you first started smoking 
daily 
Age in years Don’t remember/not sure  
2C  On average, how many cigarettes do you smoke 
each day 
Enter number 
2D   Have you had advice from a health worker to stop 
smoking in the past year 
Yes: goto 2J No: goto 2J 
 
2E   In the past, did you ever smoke daily Yes: goto 2F No: goto 2J 
2F  How old were you when you first started smoking 
daily 
Age in years Don’t remember/not sure 
2G  How old were you when you stopped smoking daily Age in years Don’t remember/not sure 
2H  On average, how many cigarettes did you smoke 
each day 
Enter number and goto 2J 
 
2J Are you currently a smoker. 







No, I quit 
within the last 
6 months 
Goto 3 
No, I quit 
more than 6 
months ago 
Goto 3 
No, I have 
never smoked 
Goto 3 
2K  In the last year, how many times 
have you quit smoking for at 
least 24 hours 
Enter number: 
Goto 2L 
2L Are you seriously thinking of 
quitting smoking.  
Choose one of the following 
options 
Yes, within the next 30 
days 
Yes, within the 
next 6 months 
No, not thinking 
of quitting 
       
 
3 I would like to ask about your current state of health.  Please indicate which of the following 
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Mobility: 
I have no problems in walking about q 
I have some problems in walking about q 
I am confined to bed q 
 
Self-Care 
I have no problems with self-care q 
I have some problems washing or dressing myself q 
I am unable to wash or dress myself q 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities q 
I have some problems with performing my usual activities q 
I am unable to perform my usual activities q 
 
Pain/Discomfort 
I have no pain or discomfort q 
I have moderate pain or discomfort q 
I have extreme pain or discomfort q 
 
Anxiety/Depression 
I am not anxious or depressed q 
I am moderately anxious or depressed q 
I am extremely anxious or depressed q 
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To help people say how good or bad their state of health is, we have 
drawn a scale (rather like a thermometer) on which the best state you can 
imagine is marked 100 and the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale, in your opinion, how good or 
bad your own health is today. Please do this by drawing a line from the 
box below to whichever point on the scale indicates how good or bad 





























state of health 
0	
Best imaginable 
state of health 
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4 [Modified St Georges Questionnaire for chronic respiratory disease patients only] 
I would now like to ask you some more detailed questions about your cough or breathing problem 
 
Questions about how much chest trouble you have had over the past 3 months. Please tick one box 
for each question: 
 
Over the past 3 months, I 
have coughed:  
 










Not at all 
Over the past 3 months, I 
have brought up 
phlegm (sputum):  
 










Not at all 
Over the past 3 months, I 
have had shortness 
of breath:  
 










Not at all 
Over the past 3 months, I 
have had attacks 
of wheezing:  
 










Not at all 
During the past 3 months 
how many severe or very 
unpleasant attacks of 
chest trouble have you 
had? 
Please tick one: 
More than 3 
attacks 
3 attacks 2 attacks 1 attack No attacks 
 
How long did the worst attack of 
chest trouble last? 
(Go to next question if you had 
no severe attacks) please tick 
one:  
A week or 
more 
3 or more days 1 or 2 days Less than a day 
 
Over the past 3 months, 
in an average week, how 
many good days 
(with little chest trouble) 
have you had? 
Please tick one:  
No good days 1 or 2 good 
days 
3 or 4 good 
days 
Nearly every 
day is good 
Every day is 
good 
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Questions about what activities usually make you feel breathless these days.  
Please tick in each box that applies to you these days: 
 True False 
Sitting or lying still    
Getting washed or dressed    
Walking around the home    
Walking outside on the level    
Walking up a flight of stairs    
Walking up hills    
Playing sports or games    
 
These are questions about how your activities might be affected by your breathing. 
Please tick in each box that applies to you because of your breathing: 
 True False 
I take a long time to get washed or dressed    
I cannot take a bath or shower, or I take a long time    
I walk slower than other people, or I stop for rests    
Jobs such as housework take a long time, or I have to stop for rests    
If I walk up one flight of stairs, I have to go slowly or stop    
If I hurry or walk fast, I have to stop or slow down    
My breathing makes it difficult to do things such as walk up hills, 
carrying things up stairs, light gardening such as weeding, dance, 
play bowls or play golf 
  
My breathing makes it difficult to do things such as carry heavy 
loads, dig the garden, jog or walk at 8 kilometers per hour, play 
tennis or swim 
  
My breathing makes it difficult to do things such as very heavy 
manual work, run, cycle, swim fast or play competitive sports 
  
                                                                                
5 I am now going to ask you some questions about the health care you have received and  the medicines 
you were given in the last year 
5A  Has a health worker examined the back of your eyes in the last year [show 
picture of ophthalmoscope eye exam] 
yes no 
5B Has a health worker examined your feet in the last year with any of the 
following [showcard picture of foot, tuning fork, pin, cotton wool] 
yes no 
5C Have you received counselling from any of the following people in the last year (counseling is not just 
receiving advice on how to take medication. It means talking with someone in a way that helps you to 
find solutions to your problems, or receive emotional support)  
 
Doctor at a clinic/outpatients Yes No 
Doctor at a general practice Yes No 
Nurse  Yes No 
Mental health nurse Yes No 
Clinic counsellor Yes No 
Social worker  Yes No 
Psychiatrist or psychologist Yes No 
Religious counsellor, traditional healer or faith healer Yes No 
 
5G Have you had a ‘flu vaccine in the last year Yes No 
5H  Has a health worker given you advice in the last year 
about weight management 
Yes No 
5I   How often do you exercise Rarely/ 1 to 3 times 1 time per 2 to 4 5 to 6 daily 
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vigorously enough to work 
up a sweat. Choose one of 
the following options: 





5J Are you taking  any medicine regularly that was 
prescribed by a doctor or nurse 
Yes: goto 5K No: goto 5L 
5K I am now going to look at your file to see what medicines have been prescribed over the last year 
5L Are you currently taking any medicine for TB yes no 
5M Are you currently taking any ARVs (antiretrovirals) yes no 
5N  How often do you miss your medication, either forgetting to 
take it or deciding not to 
Never/very 
rarely  
sometimes  often  
5O  I am now going to take your second blood pressure reading 
 
6 We would like to understand how much time and money your illness costs you. In order to do this we need 
to ask some questions about your use of health care services, your employment status and income. We 
would like to remind you that all the information you give us is confidential. 
6A Have you had a chest x-ray 
over the last 3 months 
Yes goto 6B No goto 6C 
6B Please state how many 
chest x-rays you have had over 
the last 3 months 
Enter number 
6C Have you had blood tests 
over the last 3 months 
Yes No 
6D How do you usually travel to 





















6E What was the distance travelled to the clinic (in 
km one way) then goto 6H 
Enter distance in km one way 
6F  Do you usually pay a transport 
fare 
Yes:Goto 6G No: goto 6H 
6G How much do you pay for a return fare  Enter amount in rands 
6H Please detail other costs 
usually associated with your visit  
Accommodation (enter amount 
in rands) 
Food (enter amount in rands) 
6I Aside from today, have you 
visited this clinic in the last 3 
months 
Yes: goto 6J No goto 6K 
6J How many times have you 
visited this clinic in the last 3 
months (excluding today)  
Enter number of visits 
6K Have you visited any other 




Yes: goto 6L No: goto 6M 
6I  Please indicate which of the following health care providers you have visited in the last 3 months. I will 
also ask you some more details about those visits. 
i) Another clinic 
ii) Hospital (outpatient visits only) 
iii) General Practitioner  
iv) Private Pharmacy  
v) Traditional healer/ herbalist 
vi) Other (please state) 
For each option selected, the following details will be asked: 
a) Number of visits in the last 3 months  
b) Did you pay a fee on your last visit Yes no 
c) If yes: What was the fee in rands R 
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d) What transport did you 
use to get to your last visit 
i)walk Ii)taxi iii)car iv)bus v) patient transport/ 
ambulance 
vi)other 
e) Did you pay a transport fare on your last visit Yes no 
f) If yes: What was the return fare in rands R 
g) If you used your own car, what was the distance travelled (in kilometers one way)  
h) Please detail other costs associated with your last 
visit 
i)accommodation ii)food 
6M Have you been admitted to 
hospital in the last 3 months 
Yes: goto 6N No: goto 6U 
6N How many times have you 
been admitted to hospital in the 
last 3 months 
Enter number:  
6O How many nights in total have 
you spent in hospital over the last 3 
months: 
Enter number: 
6P What is the total amount you 
have had to pay for your 
admissions over the last 3 months 
(your out-of-pocket expenses) 
Enter amount in rands:  
6Q For the most recent admission to hospital please provide the following details: 
How did you travel to the 





















6R What was the distance travelled to the hospital 
(in km one way) then goto 6U 
Enter distance in km one way: 
6S Did you pay a transport fare Yes:Goto 6T No: goto 6U 
6T How much did you pay for a return fare Enter amount in rands 
 
6U Which of the following best describes your employment status? Choose one : 
Employed  
 
How much did you earn last month (excluding grant income) 
How many days were you unable to work because of illness in the last 3 months 
(including health care visits) 
How much income have you lost in the last 3 months as a result of not being able to 
work because of any illness 
Self-employed How much did you earn last month (excluding grant income) 
How many days were you unable to work because of illness in the last 3 months 
(including health care visits) 
How much income have you lost in the last 3 months as a result of not being able to 
work because of any illness 
Student/learner 
  
How many days have you been unable to attend school/college because of illness in 
the last 3 months (including health care visits) 
Unemployed and 
looking for work 
 
Unemployed and not 
looking for work 
 
 
6V Are you getting a pension or grant (eg disability or child 
care grant) 
Yes: goto 6W No: goto 6X 
6W What was your total grant income in the last month  Enter amount in rands 
6X Have you lost your job or resigned because of illness 
during the past year 
Yes: goto 6Y No: goto 7 
6Y Before you lost your job or resigned, how much did you 
earn in the last month you worked (excluding grant income) 
Enter amount in rands 
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6Z Since losing your job or resigning, have you got another 
job 
Yes: goto 8 No: goto 8 
8  I am now going to take your third blood pressure reading, height, weight, waist circumference and hip 
measurement.  
9  If a blood test is required: When did you last have 
anything to eat or drink, other than water  
Date:  Time: 
10  It is important for our study that we interview you once more, in 14 months time. I will schedule that 
appointment for you now and we will send you SMS reminders from 3 months before the appointment. I will 
provide you with a contact number. Please let us know if your cell phone number changes or if you need to 
reschedule the appointment. In order to make it as easy as possible to contact you if necessary, I would be 
grateful if you could provide as many of the following contact details as possible: 
Home address  
Telephone number at home  
Cell phone number  
Work address  
Work telephone number  
Alternative number (friend, relative, neighbour)  
Clinic folder number  
Re-enter clinic folder number  
Name of hospital patient attends  
Hospital folder number if available  
ID number  
Re-enter ID number  
 
We would like to thank you very much for your time today. We look forward to seeing you next year.  
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Questionnaire for patients eligible for Validation Study only:  
 
I am now going to go through the questionnaire with you. We will need to take three blood pressure 
readings during the course of the interview, at least two minutes apart. [interviewer to take first blood 
pressure reading now].   
 
1. Has a doctor or nurse ever told you that you have or have had diabetes (‘sugar’) Yes No 
 
2.: Are you taking  any medicine regularly that was prescribed by a doctor or nurse for high 
blood pressure (hypertension) fieldworker to confirm from prescription charts 
Yes No 
 
3. Are you taking any medicine regularly that was prescribed by a doctor or nurse for 
cholesterol fieldworker to confirm from prescription charts 
Yes No 
 
4. I am now going to look at your file to see what medicines have been prescribed for hypertension and 
cholesterol  
 
[interviewer to take second blood pressure reading if ≥2 minutes since first reading] 
 
5. Do you currently smoke cigarettes daily Yes:  No:  
 
6. How often do you exercise vigorously 
enough to work up a sweat. Choose one of 
the following options:  
Rarely/ 
never 
















7. In case we need to contact you, I would be grateful if you could provide as many of the following 
contact details as possible: 
Home address  
Telephone number at home  
Cell phone number  
Work address  
Work telephone number  
Alternative number (friend, relative, neighbour)  
Clinic folder number  
Re-enter clinic folder number  
Name of hospital patient attends  
Hospital folder number if available  
ID number  
Re-enter ID number  
 
8. I am now going to take your third blood pressure reading, height, weight, waist circumference and hip 
measurement. You will require a blood test.  You will not require a blood test 
9 .If a blood test is required: When did you last have anything to eat or drink, other 
than water  
Date:  Time: 
 
We would like to thank you very much for your time today. We will not need to interview you again and we 
wish you well.  
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Appendix A7. PC101 trial follow-up questionnaire 
 
Thank you for returning for your Chronic Disease Study follow-up interview.  
 
 
1 I would like to start by checking 
which language you would like to use 
for the interview: 
i) English ii) Afrikaans iii) IsiXhosa 
 
2 Date of interview:  
3 Clinic: 
4 Interviewer Code: 
 
We have checked our records and we are not able to find a complete consent form for you. Please could we ask that you sign 
the same form again now. Patient information sheet and consent form here 
 
5 I would like to ask about your current state of health.  Please indicate which of the following statements best describe 
your health state TODAY (choose one option per group) EQ5D here 
 
6 I am now going to take your first blood pressure reading 
 
7A We would like to know in more detail about how you felt, not just today, but over the past week.  
I am going to read a list of some of the ways you may have felt or behaved. Using the showcard, please indicate how 
often you have felt this way during the past week.  Interviewer mark one option on each line. CESD10 here. 
 
7B Has the thought of ending your life been on your mind Yes No 
 
8A I would now like to ask you some more detailed questions about your cough or breathing problem that you reported at 
our first interview (Questions 8A-8F for respiratory cohort patients only) SGRQ for English and Afrikaans here 
 
 9  I am now going to ask you some questions about smoking 
 
9A Are you currently a smoker. Choose one 




ii)No, I quit 
within the last 
6 months 
iii)No, I quit 
more than 6 
months ago 
iv)No, I have never 
smoked 
Go to 10 
8B Since our interview about a year ago, have you had to visit a doctor or nurse because your chest 
was bad, but not including routine check-ups and visits just to collect medicines. 
Yes: go 
to 8C 
No: go to 
8F 
8C Number of clinic or general practice (GP) visits for a bad chest Enter number: 
8D Number of hospital casualty or emergency visits for a bad chest Enter number: 
8E Number of hospital admissions for a bad chest (when you have spent at least one night in 
casualty, emergency ward, or hospital): 
Enter number: 
8F Since our interview about a year ago, how many times have you had to take short courses of 
steroids (4-8 small white pills a day) for your chest problem 
Enter number: 
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Go to 9B 
 
Go to 10 Go to 10 
9B  On average, how many cigarettes do you smoke each day Enter number 
9C Since our interview about a year ago, how 
many times have you quit smoking for at 
least 24 hours 
Enter number: 
 
9D Are you seriously thinking of quitting 
smoking.  
Choose one of the following options 
i)Yes, within the next 
30 days 
ii)Yes, within the 
next 6 months 
iii)No, not thinking of quitting 
9E Since our interview about a year ago, has a health worker advised 
you to stop smoking? 
Yes No 
       
10 
 
I would like to ask you a few questions about your health and the healthcare you have received.  
Since our interview about a year ago, has a health worker given you a new diagnosis of any of the following: 
10A  high blood pressure (hypertension) Yes No 
10B  diabetes (‘sugar’) Yes No 
10C Asthma, chronic bronchitis or emphysema Yes No 
10D TB  Yes: go to 10E No: go to 10F 
10E When did you start treatment for TB Drop down options for month and year, or not yet 
started 
10F Depression Yes No 
10G Has a health worker examined the back of your eyes since our interview 
about a year ago [fieldworker to show picture of ophthalmoscope eye 
exam] 
Yes No 
10H Has a health worker examined your feet with any of the following since our 
interview about a year ago [fieldworker to show picture of foot, tuning fork, 
pin, cotton wool] 
Yes No 
10I Have you had a ‘flu vaccine since our interview 
about a year ago 
Yes No 
 
10J  Have you had a chest x-ray  since our interview about a year ago Yes go to 10K No go to 10L 
10K  Please state how many chest x-rays you have had since our interview 
about a year ago 
Enter number 
 
10L  Have you had blood tests  since our interview about a year ago Yes No 
10M  Has a health worker given you advice about weight management since 
our interview about a year ago 
Yes No 
10N Have you received counselling from any of the following since our interview about a year ago (counseling is not just 
receiving advice on how to take medication. It means talking with someone in a way that helps you to find solutions to 
your problems, or receive emotional support)  
 
i) Doctor at a clinic/outpatients Yes No 
ii) Doctor at a general practice Yes No 
iii) Nurse  Yes No 
iv) Mental health nurse Yes No 
v) Clinic counsellor Yes No 
vi) Social worker  Yes No 
vii) Psychiatrist or psychologist Yes No 
viii) Religious counsellor, traditional healer or faith healer Yes No 
 
 
11 I am now going to take your second blood pressure reading 
 
12  We now want to ask you a few questions about how your health may affect the things you do: WHODAS2 here 
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13 We would like to understand how much time and money your illness costs you. In order to do this we need to ask some 
questions about your use of health care services, your employment status and income. We would like to remind you 
that all the information you give us is confidential. 
13A  How do you usually 
travel to this clinic 
(choose one of the 
following options) 
i)Walk  





vehicle (such as car) 
go to 13B 
iv)Bus 




go to 13C 
vi)Other 
(specify) 
go to 13C 
13B  What was the distance travelled to the clinic (in km one way) Enter distance in km one way then go to 
13E 
13C   Do you usually pay a transport fare Yes: go to 13D No: go to 13E 
13D  How much do you pay for a return fare Enter amount in rands 
13E  Please detail other costs usually associated 
with your visit 
i)Accommodation 
(enter amount in 
rands) 
ii)Food (enter amount in rands) 
13F  Aside from today, have you visited this clinic in 
the last 3 months 
Yes: go to 13G No: go to 13H 
13G  How many times have you visited this clinic in 
the last 3 months (excluding today) 
Enter number of visits 
 
13H  Have you visited any other health care 
provider in the last 3 months 
Yes: go to 13I No: go to 13J 
 
13I  Please indicate which of the following health care providers you have visited in the last 3 months. I will also ask you 
some more details about those visits. 
 
i) Another clinic 
ii) Hospital (outpatient visits only) 
iii) General Practitioner  
iv) Private Pharmacy  
v) Traditional healer/ herbalist 
vi) Other (please state) 
For each option selected, the following details will be asked: 
a) Number of visits in the last 3 months  
b) Did you pay a fee on your last visit yes no 
c) What was the fee in rands R 
d) What transport did you use to 
get to your last visit 
i)walk Ii)taxi iii)car iv)bus v) patient transport/ ambulance vi)other 
e) Did you pay a transport fare on your last visit yes no 
f) What was the return fare in rands R 
g) If you used your own car, what was the distance travelled (in kilometers one way)  
h) Please detail other costs associated with your last visit i)accommodation ii)food 
 
13J  Have you been admitted to hospital in the last 3 months Yes: go to 13K No: go to 13R 
13K  How many times have you been admitted to hospital in the last 3 
months 
Enter number:  
13L   How many nights in total have you spent in hospital over the last 
3 months: 
Enter number:  
13M  What is the total amount you have had to pay for your 
admissions over the last 3 months (your out-of-pocket expenses) 




For the most recent admission to hospital please provide the following details: 
13N  How did you travel to the 


















go to 13P 
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as car) 
go to 13O 
go to 13P 
13O  What was the distance travelled to the hospital (in km 
one way) 
Enter distance in km one way then go to 13R 
13P  Did you pay a transport fare Yes: go to 13Q No: go to 13R 
13Q  How much did you pay for a return fare Enter amount in rands 
 
13R Which of the following best describes your employment status. Choose one : 
i) Employed  
 
a) How much did you earn last month (excluding grant income) 
b) How many days were you unable to work because of illness in the last 3 
months (including health care visits) 
c) How much income have you lost in the last 3 months as a result of not 
being able to work because of any illness 
ii) Self-employed a) How much did you earn last month (excluding grant income) 
b) How many days were you unable to work because of illness in the last 3 
months (including health care visits) 
c) How much income have you lost in the last 3 months as a result of not 
being able to work because of any illness 
iii) Student/learner   a) How many days have you been unable to attend school/college because 
of illness in the last 3 months (including health care visits) 
iv) Unemployed and looking for 
work 
 




13S  What is the highest level of 
education you have 
achieved 







13T  Are you getting a pension or grant (eg disability or child care 
grant) 
Yes: go to 13U No: go to 13V 
13U  What was your total grant income in the last month Enter amount in rands 
13V  Have you lost your job or resigned because of illness since 
our interview about a year ago 
Yes: go to 13W No: go to 13Y 
13W  Before you lost your job or resigned, how much did you earn 
in the last month you worked (excluding grant income) 
Enter amount in rands 
13X  Since losing your job or resigning, have you got another job Yes No 
13Y  Have you moved house since our interview about a year ago: Yes: go to 13ZZ No: go to 10Z 
13Z  How many rooms does your house have (excluding bathroom and kitchen)  
13ZZ  How many people are living with you in your house  
13ZZZ  Has the number of people living with you in your house changed since our 
interview about a year ago 
Yes No  
 
14 I am now going to take your third blood pressure reading, height, weight, and waist measurement. 
 
15 I am now going to ask you a few questions about medication you might be taking. This is very important information for 
understanding the care you are receiving. 
15A Are you currently taking any medicine regularly that was prescribed by 
a doctor or nurse 
Yes: go to 15B No: go to 15F 
15B Where do you collect your regular medication i)At this clinic 
 
ii)At another site: 
enter name of site 
15C Are you currently taking any ARVs (antiretrovirals) yes no 
 
For patients in the hypertension cohort only: None Some Most All the Not Don’t 
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time applicable know 
15D How often do you forget to take your high blood 
pressure medicine 
      
15E How often do you decide not to take your high blood 
pressure medicine 
      
15F How often do you eat salty food       
15G How often do you miss scheduled appointments       
15H How often do you run out of high blood pressure pills       
15I How often do you skip your high blood pressure 
medicine 1-3 days before you go to the clinic 
      
15J How often do you miss taking your high blood pressure 
pills when you feel better 
      
15K How often do you miss taking your high blood pressure 
pills when you feel sick 
      
15L How often do you take someone else’s high blood 
pressure pills 
      
15M How often do you miss taking your high blood pressure 
pills when you care less 
      
 
16   I would be grateful if you could confirm the following details 
16A  Full clinic folder number (including letters and numbers)  
16B   Re-enter clinic folder number  
16C   Colour or letter on folder for chronic medication if available  
16D   Name of hospital patient attends  
16E   Hospital folder number if available  
16F   ID number only if ID number was missing or not valid at baseline  
16G   Re-enter ID number  
 
17 Before we finish I would like to confirm what medication has been prescribed since our interview about a year ago. 
 
18 We would like to thank you for taking part in this study and as a token of our appreciation, we would like to give you a 
voucher of R100 to use at a store close to where you live. We thank you for your time and wish you well. 
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(n = 3694)  
Yes 
(n = 699) 
Do you have cough or difficulty breathing  
which has lasted for > 2 weeks? 
Yes 
Excluded from CRD cohort = 3236  Included in CRD cohort = 1157 
Have you been on treatment for TB 
treatment in the past 3 months? 
Yes No 
No 
(n = 458) 
Are you taking medicine for asthma, chronic bronchitis or emphysema? 
(n= 4393) 
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Appendix C3. Author Guidelines for the South African Medical Journal 
 
 




The SAMJ has launched a new submission and tracking system. Authors will be required to 
register a profile on the Editorial Manager platform in order to submit a manuscript. To 
submit a manuscript, please proceed to the SAMJ Editorial Manager website:  
www.editorialmanager.com/samj 
  




Please view the Author Tutorial for guidance on how to submit on Editorial Manager.  
  
Please take the time to familiarise yourself with the policies and processes below. If you still 




• Types of articles considered by the SAMJ  
• Article Processing Charges 
• Authorship 
• Conflict of interest 
• Research ethics committee approval 
• Clinical trials 
• Protection of patient’s rights to privacy 
• Copyright notice 
• Privacy statement 




• Preparing an article for anonymous review 
• General article format/layout 





From submission to acceptance 
• Submission and peer-review 
• Production process 
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Publication 
• Online versus print 





Type of articles considered by the SAMJ 
 
The SAMJ will no longer limit the articles accepted to those that have ‘general medical 
content’, but is intending to capture the spectrum of medical and health sciences, grouped by 
relevance to the country’s burdens of disease. This content will include research in the social 
sciences and economics that is relevant to the medical issues around our burden of disease. 
Please see ‘A new vision for the SAMJ – and a call for papers’ for a full discussion of the 
new directions for the SAMJ. 
 
We accept the following types of articles: 
• Research 
• Reviews 
• Clinical trials 
• Editorials 
• In Practice (Previously Forum incl. Case Reports) 
• Correspondence 
• Obituaries 
• Book reviews 
• Ad hoc supplements e.g. guidelines, conference/congress abstracts, Festschrifts* 
  
The following articles are by invitation only: 
• Guest editorial 
• Continuing Medical Education (CME) 
 
*Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 




All articles published in the South African Medical Journal are open access and freely 
available online upon publication. This is made possible by applying a business model to 
offset the costs of peer review management, copyediting, design and production, by charging 
a publication fee of R5 000 (ex vat) for each research article published. The charge applies 
only to Research articles submitted after 1 March 2017. The publication fee is standard and 
does not vary based on length, colour, figures, or other elements. 
 
When submitting a Research article to the SAMJ, the submitting author must agree to pay the 
publication fee should the article be accepted for publication. The publicaiton fee is payable 
when your manuscript is editorially accepted and before production commences for 
publication. The submitting author will be notified that payment is due and given details on 
the available methods of payment. Prompt payment is advised; the article will not enter into 
production until payment is received.  
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Queries can be directed to claudian@hmpg.co.za. 
 
Please refer to the section on ‘Sponsored Supplements’ regarding the publication of 





Named authors must consent to publication. Authorship should be based on: (i) substantial 
contribution to conceptualisation, design, analysis and interpretation of data; (ii) drafting or 
critical revision of important scientific content; or (iii) approval of the version to be 
published. These conditions must all be met (uniform requirements for manuscripts 
submitted to biomedical journals; refer to www.icmje.org) 
  
If authors’ names are added or deleted after submission of an article, or the order of the 
names is changed, all authors must agree to this in writing. 
  
Please note that co-authors will be requested to verify their contribution upon submission. 
Non-verification may lead to delays in the processing of submissions. 
 
Author contributions should be listed/described in the manuscript. 
  
Conflicts of interest 
 
Conflicts of interest can derive from any kind of relationship or association that may 
influence authors’ or reviewers’ opinions about the subject matter of a paper. The existence 
of a conflict – whether actual, perceived or potential – does not preclude publication of an 
article. However, we aim to ensure that, in such cases, readers have all the information they 
need to enable them to make an informed assessment about a publication’s message and 
conclusions. We require that both authors and reviewers declare all sources of support for 
their research, any personal or financial relationships (including honoraria, speaking fees, 
gifts received, etc) with relevant individuals or organisations connected to the topic of the 
paper, and any association with a product or subject that may constitute a real, perceived or 
potential conflict of interest. If you are unsure whether a specific relationship constitutes a 
conflict, please contact the editorial team for advice. If a conflict remains undisclosed and is 
later brought to the attention of the editorial team, it will be considered a serious issue 
prompting an investigation with the possibility of retraction. 
  
Research ethics committee approval 
 
Authors must provide evidence of Research Ethics Committee approval of the research 
where relevant. Ensure the correct, full ethics committee name and reference number is 
included in the manuscript. 
 
If the study was carried out using data from provincial healthcare facilities, or required active 
data collection through facility visits or staff interviews, approval should be sought from the 
relevant provincial authorities. For South African authors, please refer to the guidelines for 
submission to the National Health Research Database. Research involving human subjects 
must be conducted according to the principles outlined in the Declaration of Helsinki. Please 
refer to the National Department of Health’s guideline on Ethics in Health research: 
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principles, processes and structures to ensure that the appropriate requirements for 
conducting research have been met, and that the HPCSA’s General Ethical Guidelines for 




As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an 
intervention, with or without a concurrent comparison/control group to study the cause-and-
effect relationship between the intervention and health outcomes. All clinical trials should be 
registered with the appropriate national clinical trial registry (or any international primary 
register, if relevant), and the trial registration number should be cited at the end of the 
abstract. All clinical trial reports must also contain a data sharing statement as per the 
recommendations of the ICMJE. Statements are to indicate: 
• whether individual deidentified participant data will be shared; 
• what data in particular will be shared; whether additional, related documents will be 
available; 
• when the data will become available and for how long; by what access criteria data 
will be shared. 
  
Please see the ICJME announcement for further details and illustrative examples of data 
sharing statements: ICMJE Data Sharing Statements for Clinical Trials 
  
Since 1st December 2005, all clinical trials conducted in South Africa have been required to 
be registered in the South African National Clinical Trials Register. The SAMJ therefore 
requires that clinical trials be registered in the relevant public trials registry at or before the 
time of first patient enrollment as a condition for publication. The trial registry name and 
registration number must be included in the manuscript. 
  
Please refer to the general guidelines for all papers at the top of this article for additional 
requirements with respect to ethics approval, funding, author contributions, etc. The format 
of original research articles should be followed for reporting of clinical trial results. 
  
Protection of rights to privacy 
 
Patient 
Information that would enable identification of individual patients should not be published in 
written descriptions, photographs, and pedigrees unless the information is essential for 
scientific purposes and the patient (or parent or guardian) has given informed written consent 
for publication and distribution. We further recommend that the published article is 
disseminated not only to the involved researchers but also to the patients/participants from 
whom the data was drawn. Refer to Protection of Research Participants. The signed consent 
form should be submitted with the manuscript to enable verification by the editorial team. 
  
Other individuals 
Any individual who is identifiable in an image must provide written agreement that the 
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Copyright remains in the Author’s name. The work is licensed under a Creative Commons 
Attribution - Noncommercial Works License. Authors are required to complete and sign 
an Author Agreement form that outlines Author and Publisher rights and terms of 
publication. The Author Agreement form should be uploaded along with other submissions 
files and any submission will be considered incomplete without it. 
   
Material submitted for publication in the SAMJ is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if the 
main findings of your paper have been presented at a conference and published in abstract 
form, to avoid copyright infringement. The SAMJ does not hold itself responsible for 
statements made by the authors. 
 
Previously published images 
If an image/figure has been previously published, permission to reproduce or alter it must be 
obtained by the authors from the original publisher and the figure legend must give full 
credit to the original source. This credit should be accompanied by a letter indicating that 
permission to reproduce the image has been granted to the author/s. This letter should be 




The SAMJ is committed to protecting the privacy of its website and submission system users. 
The names, personal particulars and email addresses entered in the website or submission 
system will not be made available to third parties without the user’s permission or due 
process. By registering to use the website or submission system, users consent to receive 
communication from the SAMJ or its publisher HMPG on matters relating to the journal or 





Use of racial or ethnicity classifications in research is fraught with problems. If you choose 
to use a research design that involves classification of participants based on race or ethnicity, 
or discuss issues with reference to such classifications, please ensure that you include a 
detailed rationale for doing so, ensure that the categories you describe are carefully defined, 
and that socioeconomic, cultural and lifestyle variables that may underlie perceived racial 
disparities are appropriately controlled for. Please also clearly specify whether race or 
ethnicity is classified as reported by the patient (self-identifying) or as perceived by the 
investigators. Please note that is not appropriate to use self-reported or investigator-assigned 
racial or ethnic categories for genetic studies. 
  
Continuing Professional Development (CPD) 
 
SAMJ is an HPCSA-accredited service provider of CPD materials. Principal authors can earn 
up to 15 CPD continuing education units (CEUs) for publishing an article; co-authors are 
eligible to earn up to 5 CEUs; and reviewers of articles can earn 3 CEUs. Each 
month, SAMJ also publishes a CPD-accredited questionnaire relating to the academic content 
of the journal. Successful completion of the questionnaire with a pass rate of 70% will earn 
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the reader 3 CEUs. Administration of our CPD programme is managed by Medical Practice 




Preparing an article for anonymous review 
  
To ensure a fair and unbiased review process, all submissions are to include an anonymised 
version of the manuscript. The exceptions to this are Correspondence, Book reviews and 
Obituary submissions. 
  
Submitting a manuscript that needs additional blinding can slow down your review process, 
so please be sure to follow these simple guidelines as much as possible: 
• An anonymous version should not contain any author, affiliation or particular 
institutional details that will enable identification. 
• Please remove title page, acknowledgements, contact details, funding grants to a 
named person, and any running headers of author names. 
• Mask self-citations by referring to your own work in third person. 
   
General article format/layout 
 
Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, which will delay publication. 
  
General: 
• Manuscripts must be written in UK English. 
• The manuscript must be in Microsoft Word format. Text must be single-spaced, in 12-
point Times New Roman font, and contain no unnecessary formatting (such as text in 
boxes). 
• Please make your article concise, even if it is below the word limit. 
• Qualifications, full affiliation (department, school/faculty, institution, city, country) 
and contact details of ALL authors must be provided in the manuscript and in the 
online submission process. 
• Abbreviations should be spelt out when first used and thereafter used consistently, 
e.g. 'intravenous (IV)' or 'Department of Health (DoH)'. 
• Include sections on Acknowledgements, Conflict of Interest, Author Contributions 
and Funding sources. If none is applicable, please state ‘none’.  
• Scientific measurements must be expressed in SI units except: blood pressure 
(mmHg) and haemoglobin (g/dL). 
• Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
• Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' but 
'50%' and '19ºC'. 
• Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not 
B for beta, etc. 
• Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
• Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
• Round brackets (parentheses) should be used, as opposed to square brackets, which 
are reserved for denoting concentrations or insertions in direct quotes. 
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• If you wish material to be in a box, simply indicate this in the text. You may use the 
table format –this is the only exception. Please DO NOT use fill, format lines and so 
on. 
  
SAMJ is a generalist medical journal, therefore for articles covering genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and correct errors wrt the above, although 
they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. ‘188del11’ can 
be glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
• Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
• HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
• OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
• Bennet et al. Standardized human pedigree nomenclature: Update and assessment of 
the recommendations of the National Society of Genetic Counselors. J Genet Counsel 
2008;17:424-433: standard human pedigree nomenclature. 
 




• In Practice and Case reports 
• Reviews 
• Clinical trials 
• Correspondence 
• Obituaries 




Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that clearly 
lay out the rationale for conducting the study. Some common reasons for conducting a study 
are: to fill a gap in the literature, a logical extension of previous work, or to answer an 
important clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods in as 
much detail as possible so that others would be able to replicate the study should they need 
to. Results should describe the study sample as well as the findings from the study itself, but 
all interpretation of findings must be kept in the discussion section, which should consider 
primary outcomes first before any secondary or tertiary findings or post-hoc analyses. The 
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conclusion should briefly summarise the main message of the paper and provide 
recommendations for further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text . 
  
Structured abstract 
• This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published 
work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the 
intervention, primary and secondary outcomes, any specific analyses that were 
done on the data. 
o Results: first sentence must be brief population and sample description; outline 
the results according to the methods described. Primary outcomes must be 
described first, even if they are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for 
further study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 
• Do not include any references in the abstracts. 
  
Here is an example of a good abstract. 
  
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
• Objectives (within Introduction/Background): a clear statement of the main aim of the 
study and the major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, randomisation, 
blinding, placebo control, case control, crossover, criterion standards for diagnostic 
tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of 
participating centres. 
• Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural 
factors (e.g. smoking status, socioeconomic group, educational attainment, co-existing 
disease indicators, etc)that may have an impact on the study results. Clearly define 
how participants were enrolled, and describe selection and exclusion criteria. 
• Interventions (within Methods): what, how, when and for how long. Typically for 
randomised controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, and those 
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• Start with description of the population and sample. Include key characteristics of 
comparison groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, where 
appropriate, the exact level of statistical significance and the number need to 
treat/harm. Whenever possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. Our house style is to 
present this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for 
mean (SD). 
• Leave interpretation to the Discussion section. The Results section should just report 
the findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings 
are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 
• Strengths and weaknesses in relation to other studies 
• The meaning of the study – e.g. what this study means to clinicians and policymakers 
• Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do 




• If illustrations submitted have been published elsewhere, the author(s) should provide 
consent to republication obtained from the copyright holder. 
• Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
• Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in 
full). 
• All images must be of high enough resolution/quality for print. 
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
• Ensure all graph axes are labelled appropriately, with a heading/description and units 
(as necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 
2.0; 3.0; 4.0 etc. 
• Scans/photos showing a specific feature e.g. Intermediate magnification micrograph 
of a low malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include 
an arrow to show the tumour. 
• Each image must be attached individually as a 'supplementary file' upon submission 
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• Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
• Large tables will generally not be accepted for publication in their entirety. Please 
consider shortening and using the text to highlight specific important sections, or offer 
a large table as an addendum to the publication, but available in full on request from 
the author 
• Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
• Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to 
consecutively in the text. 
• Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
• Ensure each table has a concise title and column headings, and include units where 
necessary. 
• Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ 
|| then ** †† ‡‡ etc. 
  
Do not: Use [Enter] within a row to make ‘new rows’: 
  
Rather: 
Each row of data must have its own proper row: 
  
Do not: use separate columns for n and %: 
  
Rather: 
Combine into one column, n (%): 
  
Do not: have overlapping categories, e.g.: 
  
Rather: 
Use <> symbols or numbers that don’t overlap: 
   
References 
 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Endnotes must not be used. 
• Authors must verify references from original sources. 
• Citations should be inserted in the text as superscript numbers between square 
brackets, e.g. These regulations are endorsed by the World Health Organization,[2] and 
others.[3,4-6] 
• All references should be listed at the end of the article in numerical order of 
appearance in the Vancouver style (not alphabetical order). 
• Approved abbreviations of journal titles must be used; see the List of Journals in 
Index Medicus. 
• Names and initials of all authors should be given; if there are more than six authors, 
the first three names should be given followed by et al. 
• Volume and issue numbers should be given. 
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• First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
• Wherever possible, references must be accompanied by a digital object identifier 
(DOI) link). Authors are encouraged to use the DOI lookup service offered 
by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata search’ 
box. 
o Look for the correct, matching article in the list of results. 
o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
  
Some examples: 
• Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking 
about glaucoma. Stat Med 1998;289(1):350-355. http://dx.doi.org/10.1000/hgjr.182 
• Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: 
Butterworth, 1975:96-101. 
• Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of 
Invading Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic 
Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 1974:457-472. 
• Internet references: World Health Organization. The World Health Report 2002 - 
Reducing Risks, Promoting Healthy Life. Geneva: WHO, 2002. 
http://www.who.int/whr/2002 (accessed 16 January 2010). 
• Legal references 
o Government Gazettes: 
National Department of Health, South Africa. National Policy for Health Act, 
1990 (Act No. 116 of 1990). Free primary health care services. Government 
Gazette No. 17507:1514. 1996. 
In this example, 17507 is the Gazette Number. This is followed by :1514 - this 
is the notice number in this Gazette. 
o Provincial Gazettes: 
Gauteng Province, South Africa; Department of Agriculture, Conservation, 
Environment and Land Affairs. Publication of the Gauteng health care waste 
management draft regulations. Gauteng Provincial Gazette No. 373:3003, 
2003. 
o Acts: 
South Africa. National Health Act No. 61 of 2003. 
o Regulations to an Act: 
South Africa. National Health Act of 2003. Regulations: Rendering of clinical 
forensic medicine services. Government Gazette No. 35099, 2012. (Published 
under Government Notice R176). 
o Bills:  
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006. 
o Green/white papers: 
South Africa. Department of Health Green Paper: National Health Insurance 
in South Africa. 2011. 
o Case law: 
Rex v Jopp and Another 1949 (4) SA 11 (N) 
Rex v Jopp and Another:  Name of the parties concerned 
1949: Date of decision (or when the case was heard) 
(4): Volume number 
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SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal - where the case was heard. Similarly, (C) woud 
indicate Cape, (G) Gauteng, and so on. 
NOTE: no . after the v 
 
• Other references (e.g. reports) should follow the same format: Author(s). Title. 
Publisher place: Publisher name, year; pages. 
• Cited manuscripts that have been accepted but not yet published can be included as 
references followed by '(in press)'. 
• Unpublished observations and personal communications in the text must not appear in 
the reference list. The full name of the source person must be provided for personal 
communications e.g. '...(Prof. Michael Jones, personal communication)'. 
  
From submission to acceptance 
 
Submission and peer-review 
 
To submit an article: 
• Please ensure that you have prepared your manuscript in line with the SAMJ 
requirements. 
• All submissions should be submitted via Editorial Manager 
• The following are required for your submission to be complete: 
o Anonymous manuscript (unless otherwise stated) 
o Author Agreement form 
o Manuscript 
o Any supplementary files: figures, datasets, patient consent form, permissions 
for published images, etc. 
• Once the submission has been successfully processed on Editorial Manager, it will 
undergo a technical check by the Editorial Office before it will be assigned to an 
editor who will handle the review process. If the author guidelines have not been 
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The following process will follow: 
1. An accepted manuscript is passed to a Managing Editor to assign to a copyeditor 
(CE). 
2. The CE copyedits in Word, working on house style, format, 
spelling/grammar/punctuation, sense and consistency, and preparation for typesetting. 
3. If the CE has an author queries, he/she will contact the corresponding author and send 
them the copyedited Word doc, asking them to solve the queries by means of track 
changes or comment boxes. 
4. The authors are typically asked to respond within 1-3 days. Any comments/changes 
must be clearly indicated e.g. by means of track changes. Do not work in the original 
manuscript - work in the copyedited file sent to you and make your changes clear. 
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5. The CE will finalise the article and then it will be typeset. 
6. Once typeset, the CE will send a PDF of the file to the authors to complete their final 
check, while simultaneously sending to the 2nd-eye proofreader. 
7. The authors are typically asked to complete their final check and sign-off within 1-2 
days. No major additional changes can be accommodated at this point. 
8. The CE implements the authors’ and proofreader’s mark-ups, finalises the file, and 
prepares it for the upcoming issue. 
  
Changing contact details or authorship 
 





Online v. print 
 
The SAMJ is an online journal. The online version of the journal is the one that has the 
widest circulation, is indexed by bibliographic databases including PubMed and SciELO, 
and is accessible in academic libraries. A printed edition , containing material selected by the 
Editor is also published each month and distributed to the membership of the South African 
Medical Association. 
   
Online 
• The full text of all accepted articles is published in full online, open access, within 4 - 
6 weeks of acceptance. 
• Citation information of each article is based on its online publication. 
• You may want to make use of the advantages of online publication e.g. specify web 
links to other sources, images, data or even a short video. 
  
Print 
• Not all articles will be selected for print. 
• An article may be selected for print in a different month from that in which it was 
published online. 
• Research articles will appear in abstract form only, if selected for a print edition. 
  




Should you become aware of an error or inaccuracy in yours or someone else’s contribution 
after it has been published, please inform us as soon as possible via an email to 
publishing@hmpg.co.za,including the following details: 
• Journal, volume and issue in which published 
• Article title and authors 
• Description of error and details of where it appears in the published article 
• Full detail of proposed correction and rationale 
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We will investigate the issue and provide feedback. If appropriate, we will correct the web 
version immediately, and will publish anerratum  in the next issue. The correction will be 
indexed, as PubMed has a function for linking errata back to the original article. All 
investigations will be conducted in accordance with guidelines provided by the Committee 




Retraction of an article is the prerogative of either the original authors or the editorial team 
of HMPG. Should you wish to withdraw your article before publication, we need a signed 
statement from all the authors. 
  
Should you wish to retract your published article, all authors have to agree in writing before 
publication of the retraction. 
Send an email to publishing@hmpg.co.za, including the following details: 
• Journal, volume and issue to which article was submitted/in which article was 
published 
• Article title and authors 
• Description of reason for withdrawal/retraction. 
  
We will make a decision on a case-by-case basis upon review by the editorial committee in 
line with international best practices. Comprehensive feedback will be communicated with 
the authors with regard to the process. In case where there is any suspected fraud or 
professional misconduct, we will follow due process as recommended by the Committee on 
Publication Ethics (COPE), and in liaison with any relevant institutions. 
  




The SAMJ has an impact factor of 1.5. 
Published articles are covered by the following major indexing services. As such articles 
published in the SAMJ are immediately available to all users of these databases, guaranteed a 
global and African audience: 
• Index Medicus (Medline/PubMed)  
• ExcerptaMedica (EMBASE) 
• Biological Abstracts (BIOSIS) 
• Science Citation Index (SciSearch) 
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Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
   
Submission Preparation Checklist 
 
As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors that 
do not adhere to these guidelines. 
1. Named authors consent to publication and meet the requirements of authorship as set 
out by the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. 
3. The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4. The manuscript is in Microsoft Word document format. The text is single-spaced, in 
12-point Times New Roman font, and contains no unnecessary formatting. 
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (PDF or jpeg). These must be submitted individually as 'supplementary files' 
(not solely embedded in the manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 




Copyright of published material remains in the Authors’ name. This allows authors to use 
their work for their own non-commercial purposes without seeking permission from the 
Publisher, subject to properly acknowledging the Journal as the original place of publication. 
 
Authors are free to copy, print and distribute their articles, in full or in part, for teaching 
activities, and to deposit or include their work in their own personal or institutional database 
or on-line website. Authors are requested to inform the Journal/Publishers of their 
desire/intention to include their work in a thesis or dissertation or to republish their work in 
any derivative form (but not for commercial use).  
 
Material submitted for publication in the SAMJ is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if the 
main findings of your paper have been presented at a conference and published in abstract 




The SAMJ is committed to protecting the privacy of the users of this journal website. The 
names, personal particulars and email addresses entered in this website will be used only for 
the stated purposes of this journal and will not be made available to third parties without the 
user’s permission or due process. Users consent to receive communication from 
	
The Burden of Chronic Respiratory Disease in the Western Cape 
Part D: Appendices 
47 
the SAMJ for the stated purposes of the journal. Queries with regard to privacy may be 
directed to publishing@hmpg.co.za. 
 
